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ABSTRACT 
The lymph nodes and gastrointestinal tract are principal sites of inflammation and T cell 
dysfunction in progressive human immunodeficiency virus type 1 (HIV) infection, and a leading 
hypothesis is that aberrant responses by innate immune cells, such as macrophages, are actively 
involved in this process.  Macrophages promote and resolve tissue inflammation in health and in 
response to pathogen insult through cytokine release, phagocytosis, and wound repair, but 
currently their role in HIV/AIDS pathogenesis remains unclear.  Using the pathogenic simian 
immunodeficiency virus (SIV)-rhesus macaque model, I investigated the macrophage response at 
different stages of SIV infection and AIDS, as well as longitudinally in macaques anticipated to 
control or progress to disease based on set-point viral load.  I hypothesized that macrophages 
promote a protective response during acute SIV infection that becomes inadequate and/or 
detrimental to the host in chronic infection and associates with disease progression.  I found that 
macrophage density uniformly increased in lymph nodes and gut mucosa in acute SIV infection 
and then declined at the onset of chronic infection except for in gut mucosa of SIV progressors, 
where macrophage numbers remained elevated and were increased above pre-infection in AIDS.  
Lymph node macrophages were activated, apoptotic, and inflammatory, spontaneously secreting 
TNF-α, IL-6, and IFN-α in the acute and chronic stages of infection with minor differences 
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between groups.  In contrast, macrophages in small intestine were functionally non-
inflammatory, except in AIDS, and macrophage phagocytic capacity in SIV progressors was 
markedly impaired, inversely correlating with gut macrophage abundance, enteropathy, and 
plasma but not tissue viral burden.  Collectively, these data suggest an inflammatory function for 
macrophages in lymph nodes that participates in SIV-associated inflammation and T cell loss but 
does not contribute to disease outcome.  At the same time, macrophages in gut mucosa appear to 
resolve rather than promote inflammation through phagocytosis, and their impairment is 
associated with hallmarks of progressive SIV infection and eventual harmful activity in AIDS.  
Defining macrophage involvement in HIV/AIDS pathogenesis could elucidate novel pathways 
for adjunctive therapeutic intervention through direct or indirect augmentation of macrophages 
and therefore has considerable public health significance.   
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1.0  INTRODUCTION 
1.1 THE HIV/AIDS PANDEMIC 
Human immunodeficiency virus type 1 (HIV) is one of the deadliest pathogens of the modern 
era.  Since its isolation and discovery in 1983, over 35 million people have died of acquired 
immunodeficiency syndrome (AIDS)-related complications, the disease caused by HIV [1, 2].  
An estimated 36.7 million people live with HIV today, and in 2015 there were a total 2.1 million 
new infections, a 6% decline from 2010 [3].  HIV is a lentivirus in the family Retroviridae that 
propagates by integrating viral DNA derived from its reversed transcribed positive sense single-
stranded RNA genome into host DNA and co-opting host cellular machinery [4].  The virus 
preferentially infects memory CD4+ T-helper (Th) cells found in blood and tissues due to their 
expression of viral receptor and coreceptor CD4 and CCR5 [5, 6].  Transmission of HIV can 
occur through sexual contact, exposure to contaminated blood (e.g., via needles or syringes), or 
from mother-to-child during pregnancy [7].  New infections are disproportionately concentrated 
in developing nations, most notably Sub-Saharan Africa, and predominantly occur among 
women, the homosexual community, and ethnic minorities [8].  The advent of antiretroviral 
therapy (ART) that suppresses viral replication has increased the average life-expectancy of 
HIV-infected individuals dramatically; however access to therapeutics is often limited in nations 
with the highest prevalence of infection [9].  A small subset of HIV+ individuals (0.15%-1.5%) 
 2 
referred to as elite controllers or long-term nonprogressors naturally maintains low or 
undetectable levels of virus replication and has delayed onset of AIDS in the absence of ART 
[10-12].  For elite controllers and the roughly 17 million individuals currently accessing ART, 
new health complications become a reality due to chronic virus exposure and/or long-term ART 
use [13, 14].  Today, non-infectious comorbidities, including neurological disorders and 
cardiovascular disease, are some of the leading causes of mortality in viral suppressed HIV-
infected individuals, who have over twice the risk of developing these diseases compared to age-
matched non-infected individuals [15, 16].  A growing body of literature suggests a driving 
factor of non-infectious comorbidities and AIDS progression is aberrant immune cell activity and 
the sustained exposure of host tissue to inflammatory mediators [17].   
1.2 SIV-NONHUMAN PRIMATE MODEL 
Our current wealth of knowledge and understanding of HIV infection is in large part due to 
studies conducted using simian immunodeficiency virus (SIV)-infected nonhuman primates.  
Experiments that would otherwise involve invasive procedures in humans, such as research into 
the gastrointestinal tract, or challenging longitudinal protocols, such as investigating the early 
events of transmission, can be carried out humanely and with precision in nonhuman primates.  
Studies using SIV and nonhuman primates have been employed to test preclinical vaccines, 
discover novel therapeutics, and expand our understanding of mechanisms underlying HIV 
disease control and progression [18].  Currently, there are 2 primary SIV/nonhuman primate 
models that dominate the HIV/AIDS scientific landscape:  endemically or experimentally 
infected natural hosts of SIV and non-natural SIV hosts that require experimental inoculation 
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[19].  African-origin nonhuman primates, for example the African green monkey (Chlorocebus 
sabaeus), co-evolved for thousands of years with SIV, resulting in adaptations that confer a 
nonpathogenic infection despite maintaining moderate levels of virus replication in blood and 
tissues [20, 21].  Conversely, experimental infection of Asian-origin macaques recapitulates 
hallmarks of pathogenic HIV infection in humans, such as systemic and mucosal immune 
pathologies, viral load dynamics, clinical symptoms, and eventual progression to AIDS, albeit at 
an accelerated rate [22, 23].  The most widely adopted model for studying progressive infection 
is the Indian-origin rhesus macaque (Macaca mulatta) infected with either pathogenic 
SIVmac251 swarm or SIVmac239 clone [18].  Studies investigating correlates of immune 
protection and disease control for therapeutic purposes and academic advancement have 
classically compared outcomes in natural SIV hosts to those in non-natural hosts, simulating 
comparisons between elite controllers and normal progressors in humans [19].  These 
comparisons have led to many seminal discoveries in the field, such as the observation that 
plasma viral burden is not the only determinant of disease progression and that gastroenteropathy 
and chronic immune activation also play a key role (to be discussed in detail in section 1.3) [18].  
One caveat to comparing outcomes in natural and non-natural SIV models (i.e., African green 
monkeys vs. rhesus macaques) for pathogenesis studies is the inability to control for species-
specific variance between animals.  The natural SIV hosts African green monkeys, sooty 
mangabeys, and mandrills, for example, have distinct immunologic imprints compared to 
pathogenic models that bestow a protective advantage, such as a lower frequency of CD4+ T 
cells in circulation and mucosal tissues and lower CCR5 expression on CD4+ T cells [24, 25].  
Moreover, the use of distinct species of nonhuman primates often requires comparing infection 
with dissimilar strains of virus.  An underused approach to control for these potentially 
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confounding variables is to exploit certain protective major histocompatibility class (MHC) I 
alleles that are associated with long-term virus control (to be discussed in detail in section 1.3).  
By taking advantage of nonhuman primate analogs to the human protective alleles HLA-B*27 
and HLA-B*57, comparisons between controlled and progressive disease outcomes in identical 
species of animal infected with the same strain of virus can be made [26].  For the purposes of 
this dissertation, from here on unless otherwise stated, all discussion of nonhuman primates will 
refer to SIV infection in Indian-origin rhesus macaques.   
1.3 HIV/SIV INFECTION DYNAMICS AND DISEASE PATHOGENESIS 
Infection of target CD4+ T cells by HIV/SIV initiates a cascade of events within the host that can 
be divided into three discrete stages:  1) the acute or primary stage of infection, 2) the chronic, 
asymptomatic period of infection, and 3) AIDS.  Clinical symptoms consistent with acute stage 
infection manifest in humans and nonhuman primates between one to four weeks after viral 
transmission [7, 27, 28].  Regardless of transmission route, acute infection is associated with a 
burst of virus replication in the plasma, which peaks on average between 105-107 viral RNA 
copies/mL, and corresponds with a decline of circulating naive CD4+ T cells from blood [29].  
Serial necropsy studies in rhesus macaques inoculated vaginally with SIVmac251 reveal that 
viral RNA is detectable as early as 24-hours post-infection in the gastrointestinal tract, tonsil, 
spleen, lymph nodes, and female reproductive tract.  In the same study, by day 10, virus could be 
found in lungs, liver, thymus, and spleen, but at the highest concentration in gastrointestinal and 
lymphoid tissues [30].  The resolution of peak viremia during the acute phase signals the onset of 
asymptomatic (or chronic) infection and coincides with an expansion of HIV/SIV-specific 
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adaptive immune responses.  Here, antigen-specific CD8+ T cells, and to a minor extent plasma 
cells, respectively combine to kill HIV/SIV-infected CD4+ T cells and neutralize free virions in 
circulation, ultimately reducing virus burden in the plasma [31, 32].  Studies have shown that 
HIV-specific CD8+ T-lymphocytes are detectable in tissues before peak viremia, however the 
magnitude and timing of their response is insufficient to overcome the rate of viral expansion 
[30, 33].  The extent with which virus replication in plasma is controlled and subsequently 
maintained throughout the asymptotic phase of infection is referred to as set-point.  Set-point 
establishes chronic phase virus load until the emergence of AIDS and is used as a reliable 
measure of the severity of infection, is associated with time to progression to disease, is 
clinically employed as a guide to determine an ART regimen, and is used to assess ART efficacy 
[34].  Definitions vary worldwide but in general elite controllers of HIV maintain median set-
point plasma virus RNA concentrations between 50-1000 copies/mL, whereas risk of rapid 
AIDS-onset is significantly increased when virus loads exceed 104 copies/mL [34, 35].  
Furthermore, plasma viral burden inversely correlates with CD4+ T cell levels in blood; 
therefore, individuals with the highest set-point viral loads tend to become immunocompromised 
more rapidly [36].  A diagnosis of AIDS is reached when circulating CD4+ T cells fall below 
200 cells/mm3, accompanied by a rise in opportunistic infections, such as Pneumocystis 
pneumonia, and in the non-infectious disorders described above.   
1.3.1 Genetic determinants of disease outcome 
Certain host genetic factors can play an important role in determining disease prognosis because 
of their influence on set-point viral load.  Two of the most well-studied genetic determinants 
associated with slow progression to disease are the CCR5-Δ32 allele and protective MHC class I 
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alleles [37, 38].  Tropism of HIV/SIV is nearly always dictated by the co-expression of cellular 
proteins CD4 and CCR5, which the viral envelope proteins gp120 and gp41 attach to for viral 
entry [4].  For a small subset of individuals, viral entry is impaired due to a 32 base-pair mutation 
in their CCR5 gene that produces a nonfunctional CCR5 receptor on the surface of their CD4+ T 
cells [37].  Heterozygous carriers of this allele have reduced susceptibility to infection and often 
maintain elite controller status, whereas homozygous expression confers complete resistance to 
viral entry [39, 40].  Interestingly, genetic polymorphisms that result in the increased circulation 
of the CCR5-ligands RANTES, MIP-1α, and MIP-1β are also associated with enhanced 
protection [41].  Despite optimism for the development of a CCR5-receptor antagonist, so far 
only one drug, maraviroc, has reached the market.  Maraviroc is detectable at high 
concentrations in blood, seminal plasma, and rectum in treated patients, and provides at 
minimum a 1.5% log reduction in plasma viral RNA compared to control groups [42, 43].   
Expression of specific MHC class I alleles in humans (referred to as HLA molecules) and 
in rhesus macaques (Mamu molecules for Macaca mulatta) can also affect the rate of 
progression to disease by promoting cytotoxic T-lymphocyte-mediated containment of viral 
expansion.  Most notably, expression of alleles HLA-B*14, -B*27, and -B*57 in humans and 
Mamu-A*001, -B*017, and -B*008 in macaques are highly correlated with low chronic phase 
viremia and increased survival time [44, 45].  Identification of these alleles has led to extensive 
research into the role of CD8+ T cell responses in virus control as well as innate immune cells 
that orchestrate effector CD8+ T cell specificity, such as myeloid dendritic cells (DCs) [46].  
Immunization and viral sequencing studies in humans and nonhuman primates demonstrate that 
blood CD8+ T cells generated by protective HLA/Mamu allele-restricted epitopes suppress viral 
replication by targeting specific regions of the virus [47, 48].  For example, in one study, 
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differences in Mamu-B*008-expressing SIV controllers (chronic phase viral loads <104 gag 
copies/mL) compared to SIV progressors (viral loads >105 copies/mL) were found to be a result 
of viral escape mutations in Mamu-B*008 restricted-epitopes and not a function of divergent 
CD8+ T cell activity or frequency in blood [48, 49].  While some studies find associations 
between enhanced CD8+ T cell responses and elite virus control, with or without expression of 
protective HLA class I alleles, there is still no clear consensus [50-54].  The fact that many 
natural controllers of HIV do not express protective class I alleles, are not carriers of the CCR5-
Δ32 polymorphism, and/or have measurable CD8+ T cell dysfunction underscores the 
complexities of immune-mediated viral suppression among HIV-infected individuals [51, 55, 
56].    
1.3.2 Pathobiology of infection in lymph nodes and gastrointestinal tract 
An overwhelming majority of research investigating HIV/SIV pathogenesis extrapolate findings 
from the blood as a window into the state of infection and disease despite blood containing 
between 0.3% and 0.5% of the total CD4+ T cells in the body [57].  Instead, secondary lymphoid 
organs and the gastrointestinal tract are the body’s largest reservoirs of CCR5-high CD4+ T cells 
in health and the most significant sites of virus replication and latency during infection [58].  
Lymphoid compartments function as infrastructure to introduce antigen-bound innate immune 
cells circulating in the periphery to naïve immature lymphocytes, an interaction essential for the 
induction of antigen-specific cellular and humoral immune responses and the development of 
immunologic memory [59].  Lymph nodes are stationed almost everywhere in the body but are 
most concentrated in and around mucosal surfaces.  In fact, roughly 85% of the body’s lymphoid 
tissue and 90% of its lymphocytes are located within the gastrointestinal tract [60-62].  Situated 
 8 
at the interface of the host and external environment, the gastrointestinal tract maintains 
physiologic and immunologic equilibrium through elaborate symbiotic interactions with 
intestinal microbiota [63].  In addition to shaping the development of antigen-specific immune 
responses, these interactions play vital roles in nutrient absorption, in preventing non-specific 
immune responses towards dietary antigens and commensal bacteria, and in combating the 
expansion of pathogenic organisms [64]. 
Among the earliest sites infected by HIV or SIV is the gastrointestinal tract [65].  The 
magnitude of CD4+ T cell depletion in gut mucosa is significantly more rapid and profound than 
in any other tissue in the body, occurring days before CD4+ T cells decline in blood and lymph 
nodes [66, 67].  Studies using the rhesus macaque SIV model demonstrate that over 90% of gut 
CD4+ T cells are depleted 2 weeks post-infection [66].  This is in part a function of the high 
density of effector memory CD4+ T cells that occupy the gut, the most readily infected of the 
CD4+ T-helper cell populations due to their high CCR5 expression and activated state [6, 66, 68, 
69].  Unlike in the blood, however, the reservoir of gut CD4+ T cells remains considerably 
depleted and dysfunctional in the chronic stages of infection and is only partially restored by 
ART medication [70].  Paradoxically, experimentally-infected natural hosts of SIV also 
experience an acute loss of CD4+ T cells from the gut, suggesting CD4+ T cell depletion from 
gastrointestinal tract is not an indicator or driver of disease progression [71].  Lymph node 
CCR5+ CD4+ T cells are also progressively depleted during HIV/SIV infection and depletion is 
strongly correlated with the degree of lymph node hyperplasia and fibrosis [72, 73].  As a 
consequence, the timing of drug commencement is inversely proportional to the extent of CD4+ 
T cell recovery in HIV-infected lymph nodes [74, 75].  
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Pathologic changes to lymph nodes and the gut during HIV/SIV infection are profound 
and play a significant role in influencing the course of disease.  In lymph nodes, changes 
associated with progressive infection include extensive collagen deposition and fibrosis, 
architectural damage, and an influx of activated, apoptotic, and dysfunctional innate and adaptive 
immune cells [74, 76-84].  Compared with SIV infection in rhesus macaques, lymph nodes from 
viremic natural SIV hosts have relatively little detectable virus, preserved tissue integrity, and no 
collagen deposition [85].  Likewise, the gastrointestinal tract is subject to a massive influx of 
activated leukocytes, alterations in gut microbiota, and extensive enteropathy [86-89].  Breach in 
the intestinal lining results in leakage of commensal microbiota from the gut luminal space into 
the host cavity which contributes to a persistent state of cellular activation throughout the body, a 
phenomenon referred to as chronic immune activation [90, 91].  In SIV-infected macaques, 
Escherichia coli (E.coli) and associated microbial products are detectable in lamina propria of 
colon as early as 2 weeks post-infection and found at high levels in colon and distal lymph nodes 
in SIV/AIDS [90].  One mechanism for intestinal breach is the depletion of the Th17 T-cell 
subset from gut lamina propria [92].  Th17 cells promote mucosal epithelial integrity by 
secreting IL-17 and IL-22, which maintain epithelial cell tight junctions, promote enterocyte 
proliferation and remodeling, and support innate defense against microbiota [93].  In contrast to 
pathogenic infection, gut Th17 cell frequencies remain stable in natural SIV hosts, despite 
ongoing virus replication in intestine, and in HIV-infected individuals that initiate ART early 
[21, 85, 94, 95].  The cumulative and sustained exposure of host cells to persistent virus 
replication and translocated bacteria, among other factors, perpetuates an environment of 
aberrant immune activity and unchecked inflammation that is highly correlated with disease 
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outcome, and the mechanisms underlying these processes are the focus of intense investigation 
[91, 96].   
1.3.3 HIV/SIV infection and innate immunity 
Mononuclear cells of the innate immune system and innate-associated responses are often 
implicated in contributing to tissue damage and immune dysfunction in HIV/AIDS.  The 
mononuclear phagocytes DCs and macrophages are hematopoietic cells that are central to 
bridging the gap between innate and adaptive immune responses [97].  There are two primary 
DC subsets found in humans and nonhuman primates:  myeloid DCs and plasmacytoid DCs.  
Myeloid DCs are dedicated antigen-presenting cells that can be productively infected by HIV 
and have been shown to trans-infect CD4+ T cells through virological synapses and endosome-
associated vesicles via tunneling nanotubes [98, 99].  Myeloid DCs accumulate in lymph nodes 
during acute SIV infection to generate antigen-specific adaptive immunity; however, infection is 
associated with their impaired maturation, resulting in reduced expression of MHC class II, 
CD40, and CCR7 and an inability to stimulate naïve CD4+ T cells, possibly a function of 
increased apoptosis [84, 100].  At the same time, plasmacytoid DCs, the foremost type I 
interferon (IFN)-producing cells in the body, accumulate in lymph nodes and gut mucosa, and 
their accumulation coincides with chronic IFN-stimulated gene expression and immune 
activation associated with pathogenic SIV infection [83, 88].  While plasmacytoid DCs are 
reported activated in acutely SIV-infected lymph nodes, they are also highly apoptotic, 
hyporesponsive to ex vivo viral stimulation, and the blockade of plasmacytoid DC IFN-α release 
has no effect on SIV-associated immune activation, suggesting other cell types participate in this 
response [83, 101, 102].  In AIDS, both DC subsets are lost in secondary lymphoid tissues, 
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suggesting a role for DCs in disease pathogenesis and highlighting the importance of defining 
mechanisms of innate immune pathology associated with divergent disease outcomes [103].  
While a lot is known about the role of DCs in HIV/AIDS, relatively little is understood about 
macrophages and their contributions to HIV pathogenesis.   
1.4 MACROPHAGES 
Macrophages are tissue-resident effector cells of the innate immune system that mediate 
homeostasis through their diverse phenotypic signatures, strong phagocytic capacity, and the 
ability to present antigen on MHC class II molecules.  They originate in tissues during 
embryonic development and can be derived and differentiated from monocytes in circulation 
during inflammation [104, 105].  Macrophages exhibit a high degree of heterogeneity and 
plasticity from tissue to tissue conferring the ability to respond to tissue-specific needs in health 
and adapt accordingly to different infections and diseases [106].  Specialized macrophages 
resident in tissues include Kupffer cells (liver), microglia (brain), dermal macrophages (skin), 
and alveolar macrophages (lung) [106].  The range of functions macrophages carry out include 
tissue maintenance and repair, the capacity to initiate and resolve inflammatory responses, 
immune surveillance and pathogen control, augmentation of adaptive immunity, and iron 
metabolism [106].  Macrophages were first discovered in 1893 by Elie Metchnikoff while 
observing large nucleated cells ingest material in the context of pathogen-induced inflammation, 
a process termed phagocytosis [107].  Phagocytosis is a type of endocytosis by which 
macrophages internalize and degrade large molecules (~0.75µm in diameter) for the purpose of 
tissue maintenance, such as clearing cellular waste or pathogenic debris, and for influencing 
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adaptive immune responses through antigen-presentation [108].  Macrophages facilitate receptor-
mediated phagocytosis by tagging cellular debris and pathogens with secreted opsonins, 
including mannose-binding lectin, fibronectin, and complement proteins (e.g., C3b) [108].  The 
capacity to present antigen on MHC class II molecules to lymphocytes and enhance their 
activation distinguishes macrophages from other phagocytic cells, such as neutrophils which lack 
surface MHC class II expression [108].  Macrophages differentiate benign host material from 
inflammatory cellular debris and microorganisms through a variety of internally and externally 
expressed pattern recognition receptors, such as Toll-like receptors (TLRs), NOD-like receptors, 
C-type lectin receptors, and scavenger receptors [109-112].  Macrophage expression of pattern 
recognition receptors varies across tissues in health reflecting their adaptation to different 
compartmentalized microenvironments [113].  As a consequence, resident macrophages have the 
capacity to contribute a spectrum of responses throughout the host that are amenable to 
maintaining homeostasis within each tissue [114].  Unlike macrophages in lymph nodes, for 
example, macrophages in the intestine constitutively downmodulate expression of 
lipopolysaccharide (LPS) co-receptor CD14, co-stimulatory molecules CD40, CD80, and CD86, 
and innate response pathway adaptor proteins MyD88 and TRIF to avoid inappropriate responses 
towards commensal enteric microbiota and food antigens [115-118].   
1.4.1 M1-M2 macrophage paradigm  
The M1-M2 classification system was designed to simplify macrophage diversity based on their 
responses to specific TLR-ligands, cytokine signals, and their induction of either Th1-cytotoxic 
or Th2-regulatory adaptive immune responses [119, 120].  Labeling of macrophages as M1- or 
M2-like represents extremes in macrophage behavior on a continuum of activity, and it is likely 
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most macrophages exist in the center of this spectrum [121].  Traditionally, tissue macrophages 
have been delineated by their expression of various surface and intracellular antigens such as 
HAM56, CD68, CD163, CD14, CD206, CD11b, CD169, and MAC387 [113, 122, 123].  
However, the promiscuity of many of these antigens on different cell-types and between M1 and 
M2 cell populations has underscored the importance of pairing surface antigen expression with 
certain gene transcriptional signatures and/or functional attributes [114].  M1 or classically 
activated macrophages are typified by their heightened antigen-presentation ability and 
disposition for cytolytic and microbicidal responses in the context of infection and disease [124].  
Polarization of M1 macrophages is driven by exposure to LPS, IFN-γ, and GM-CSF which 
induce an enhanced capacity for the production of pro-inflammatory mediators IL-6, TNF-α, IL-
1β, and iNOS [125, 126].  Due to their direct-killing function, M1 macrophages are found 
activated and in abundance in tissues infected with many intracellular bacterial pathogens such 
as Salmonella typhi, Mycobacterium tuberculosis, and Listeria monocytogenes [127-129].  For 
example, granuloma lesions in M. tuberculosis infection of cynomolgus macaques and humans 
are characterized by clusters of M1 macrophages within the inner regions that may function to 
restrict bacteria growth [130].  M1 macrophages also exhibit antitumor potential [124].  Studies 
in lung cancer models have uncovered benefits of M1 macrophage cytolytic activity in 
suppressing tumor cell growth and metastasis by decreasing tumor cell viability [131].  
Irregularity of M1 macrophage activity, however, can be a source of tissue pathology in chronic 
infections and non-infectious diseases.  Crohn’s disease is a chronic intestinal disorder associated 
with a disrupted intestinal barrier and an infiltration of TNF-α- and iNOS-expressing 
macrophages [132].  The FDA approved biologics Natalizumab (an anti-α4 integrin antibody) 
and Adalimumab (an anti-TNF-α antibody) are currently marketed for treatment of Crohn’s 
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disease-associated inflammation by inhibiting M1 macrophage recruitment to and related-
responses within the gut mucosa [133, 134].     
M2 or alternatively activated macrophages sit at the opposite end of the spectrum from 
M1 macrophages.  Activation and accumulation of M2 macrophages are correlated with tissue 
repair and remodeling as well as the resolution of inflammation, and they are found in the 
presence of fungal, helminth, bacterial, and some viral infections [124].  For example, lack of an 
early M2 response in respiratory syncytial virus-infected mice results in protracted 
proinflammatory activity by recruited immune cells within the lung and is correlated with 
increased alveolar pathology [135].  Gene expression associated M2 polarization, such as Arg1, 
Fn1, and Egr2 are increased in the presence of IL-4, IL-10, IL-13, and M-CSF, and 
downregulated in response to LPS and IFN-γ [126, 136].  M2 macrophages can be loosely 
phenotyped by their expression of arginase-1, CD206, and CD163, however in some instances 
these markers have been found on M1-like cells [113].  For example, tissues from patients with 
Crohn’s disease, infectious mononucleosis, and Hodgkin’s lymphoma, all conditions associated 
with a Th1-predominant phenotype, have an abundance of CD163-positive macrophages 
expressing signature M1-like genes [137, 138].  While not as efficient at presenting antigen as 
M1 cells, M2 macrophages excel at phagocytosis and have high expression of scavenger 
receptors that facilitate endocytic clearance of inflammatory cellular byproducts, bacterial 
endotoxins, and IgG-opsonized pathogens [113].  The scavenger receptor CD163, for instance, 
has a strong binding affinity for hemoglobin-haptoglobin complexes [139].  A byproduct of 
hemolysis, hemoglobin can induce inflammatory IL-8 and TNF-α responses from leukocytes 
[140, 141].  CD163-expressing macrophages actively patrol tissues and scavenge for hemoglobin 
to prevent hemoglobin-induced cytotoxicity [142].  M2 macrophages also mediate wound repair 
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and angiogenesis by production of growth factors such as VEGF-A, IGF-1, and HGF, and 
studies in Crohn’s disease patients have shown inadequate HGF secretion is associated with 
reduced intestinal healing [143, 144].  Similarly, the production of TGF-β by M2 macrophages 
also encourages tissue healing by promoting fibroblast growth, which has been found to decrease 
plaque rupture in atherosclerosis by increasing plaque stability [145].  Chronic production of 
growth factors can conversely fuel tumor cell expansion, and studies have shown that tumor 
microenvironments actively produce signals to recruit and polarize macrophages towards an M2 
phenotype, making them an enticing target for anti-cancer therapeutics [146, 147].  In this 
document, I use the marker CD163 to define macrophages independent of M1/M2 because of its 
strict expression by cells of the monocyte/macrophage lineage.   
1.4.2 Dynamics of macrophages during HIV/SIV infection 
Infection with HIV in humans and SIV in rhesus macaques is associated with a marked increase 
in macrophage abundance in the lymph nodes, spleen, lung, heart, brain, small intestine, and 
colon, suggesting an important role for macrophages in HIV/SIV pathogenesis [89, 148-154].  
Increased macrophage numbers in the lung, duodenum, spinal cord, and brain have been found to 
associate with pronounced monocyte activation, turnover, and trafficking, implicating monocytes 
as a potential source of newly recruited macrophages in HIV/SIV infection [89, 149, 155, 156].  
Under homeostatic conditions, monocytes exist as three discreet subsets in blood, identified as 
either CD14+CD16- (classical), CD14+CD16+ (intermediate), or CD14-CD16+ (nonclassical), 
the former constituting roughly 80% of all monocytes [157].  Increasing CD16 expression on 
monocytes is reflective of monocyte maturation, and HIV infection is associated with a 
preferential expansion of CD16-high monocytes in circulation [158-161].  In ART-treated 
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macaques with acute SIV infection, macrophage abundance is significantly diminished compared 
to ART-naïve animals and coincides with decreased monocyte BrdU incorporation, a measure of 
recent cell division, suggesting a relationship between macrophage recruitment to tissues and 
plasma viral burden [101].  Furthermore, inhibition of monocyte trafficking correlates with 
reduced macrophage burden in heart and dorsal root ganglia, providing convincing evidence for 
monocytes as a mechanism of macrophage accumulation in HIV/SIV-infected tissues [155, 162].  
1.5 PUTATIVE CONTRIBUTIONS OF MACROPHAGES TO HIV/SIV 
PATHOGENESIS 
1.5.1 Macrophages as targets of HIV/SIV infection 
One means by which macrophages might contribute to HIV/SIV pathogenesis is by serving as 
targets of viral infection.  Macrophages are among the first cells infected in tissues after viral 
transmission, along with other myeloid cell types and Th17 cells, and it is posited the main 
mechanism by which they acquire virus is through phagocytosis of infected CD4+ T cells [163-
165].  Some studies have demonstrated that macrophages can also transmit virus and establish de 
novo infection of CD4+ T cells through virological synapses and the secretion of virus-
containing exosomes or trans-infection [166-170].  Although the number of virus infected 
macrophages is low relative to CD4+ T cells, macrophages do represent an important 
longstanding source of replication competent virus due in part to inefficient suppression of viral 
replication by cytotoxic CD8+ T cells [171-174].  Viral RNA and DNA have been detected in 
macrophages located within lymph nodes, lung, heart, liver, spleen, central nervous system, 
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brain, and regions of the gastrointestinal tract, and infection has been implicated in driving 
aberrant macrophage activity that may promote focal inflammation and immune dysfunction 
[175-181].  Monocytes also represent a pathway to infection as macrophage precursors that cross 
the blood-tissue barrier and differentiate into newly immigrated macrophages [182, 183].  CD16-
expressing monocytes are preferentially infected by HIV due to their expression of CCR5 
compared to other monocyte subsets and are found significantly diminished in frequency in 
ART-treated individuals and elite controllers [184-187].  It is currently unclear how ART-
mediated suppression of virus effects the ratio of viral positive to viral negative macrophages in 
tissues.  Despite ART-treatment, HIV DNA and p24 are detectable in macrophages from brain, 
duodenum, and lung from HIV-infected individuals, and therefore macrophages can function as 
persistent sources of new virion production in the presence or absence drugs [181, 188, 189].    
1.5.2 Alterations in macrophage function during HIV/SIV infection 
In addition to being reservoirs for viral antigen, abnormalities in macrophage functional behavior 
are implicated in both directly and indirectly contributing to HIV/AIDS pathogenesis.  To date, a 
preponderance of evidence supports a pathologic or detrimental role for macrophages in 
HIV/SIV-infected tissues.  In SIV-infected lymph nodes, lung, and heart, increased macrophage 
numbers correspond with increased lymphoid fibrosis, pulmonary tissue destruction, and cardiac 
pathology, respectively [149, 190].  In addition, macrophage and monocyte activation as 
measured by plasma soluble CD163 (sCD163) levels is strongly correlated with measures of 
systemic T cell activation, plasma viral burden, neurocognitive impairment, and atherosclerotic 
plaque buildup [191-193].  The level of monocyte turnover from the bone marrow is 
significantly correlated with plasma sCD163 levels and has been shown to be a strong predictor 
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of progression to AIDS [194, 195].  Moreover, recent studies demonstrate that antibody-
mediated suppression of monocyte migration to heart and brain decreases focal inflammation and 
tissue pathology and is associated with reduced tissue macrophage density [155, 162].  In HIV-
infected colon, macrophage recruitment is positively correlated with the level of LPS in plasma, 
associated with in situ expression of TNF-α and IL-1β, and they display increased 
responsiveness to ex vivo LPS stimulation compared to uninfected controls [196].  
Alternatively, evidence also exists that suggests macrophage dysfunction might indirectly 
contribute to disease pathogenesis due to an inadequate or weakened immune response during 
infection.  Reported macrophage and monocyte phagocytic defects coincide with the emergence 
of several opportunistic pathogens in HIV/AIDS [197-199].  During the chronic stages of 
infection, in SIV-infected colon and HIV-infected duodenum, macrophage phagocytic capacity is 
significantly impaired and associated with increased E.coli products in plasma and tissues [89, 
90, 200].  Moreover, some in vitro and in vivo assessments reveal widespread deficiencies in 
macrophages’ ability to respond to HIV antigens and in HIV/SIV infection [101, 201, 202].  For 
example, while in situ stained macrophages in acute SIV-infected lymph nodes co-express TNF-
α and IFN-α, lymph node macrophages stimulated ex vivo with SIV env nucleotides produce 
significantly less TNF-α and IFN-α compared to in health [101, 102].  In lung, alveolar 
macrophages ability to convey an effective cytokine response towards bacterial pneumonia is 
impaired in the context of HIV infection [203].  Furthermore, impaired macrophage cytokine 
responses are also implicated in contributing to inadequate CD4+ T cell proliferation and IFN-γ 
production in SIV-infected lymph nodes [100].   
Lastly, some findings are consistent with a beneficial or nonpathologic role for 
macrophages in HIV/SIV infection.  In vitro HIV infection of monocyte-derived macrophages 
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does not induce expression of Nf-κB, IRF3, and other inflammatory-related transcription factors, 
suggesting inflammatory M1-type macrophages do not arise from virus exposure [204].  
Additionally, some studies report enhanced production of anti-inflammatory IL-10 from 
macrophages after exposure to HIV proteins gp120 and Tat, which in turn might inhibit 
inflammatory IL-12 [205-207].  CD163 is upregulated by microglia in encephalitic brain during 
chronic SIV infection and found co-localizing with haptoglobin, an indicator of a breach in the 
blood-brain barrier, suggesting macrophage-mediated clearance and degradation [208].  On the 
other hand, increased macrophage density in the brain may be a double-edge sword, 
complicating interpretations of macrophage mobilization to brain and perhaps other tissues.  
Several studies have shown an aberrant monocyte/macrophage response may underlie HIV-
associated dementia, encephalitis, and neurocognitive degeneration, with the level of 
monocyte/macrophage accumulation associated with increased macrophage-derived 
proinflammatory mediators and increased disease severity [156, 194, 209, 210].  
Despite an abundance of literature regarding phenotypic and functional alterations in 
macrophages associated with progressive HIV/SIV infection, to date no studies have addressed 
the macrophage response in the context of stable or controlled infection.  Furthermore, whether 
infection-mediated changes in macrophages within peripheral tissues parallel changes in mucosal 
sites is currently unclear, as few studies have addressed the anatomical relationship of the 
macrophage response in the context of divergent disease outcomes.  This represents a major 
barrier to progress in the field and complicates our understanding of how macrophages 
contribute to HIV/AIDS pathogenesis.   
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Macrophages accumulate in tissues including the principal viral reservoirs lymph nodes and gut 
mucosa during HIV and pathogenic SIV infections, and measures of macrophage activation are 
strongly correlated with progression to AIDS.  Nevertheless, much of what we know about 
macrophage involvement in HIV/SIV infection is based on conclusions drawn from findings in a 
single tissue compartment and in the context of a single disease state.  Whether these findings 
suggest that differences in the macrophage response to infection are desirable or detrimental is 
currently unclear and is a major impediment to our understanding of HIV/AIDS pathogenesis.  In 
the present study, I will investigate macrophages in lymph nodes and gut mucosa across different 
stages of SIV infection and prospectively in animals that develop diverging disease courses.  
This multifaceted approach will allow for the analysis of anatomical differences in macrophage 
function as it relates to infection stage and disease status, as well as the analysis of events before 
and after SIV control is achieved and how those events differ in animals predicted to progress to 
AIDS.  I hypothesize that macrophages promote a protective response during acute SIV 
infection that becomes inadequate and/or detrimental to the host in chronic infection and 
associates with disease progression.  To address this hypothesis, I propose three specific aims: 
 
Aim 1:  Assess how different stages of SIV infection and AIDS impact macrophage 
frequency and turnover in lymph nodes and small intestine.  Using a cross-sectional 
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approach, I will evaluate changes in macrophage kinetics with archived samples of lymph node 
and gut mucosa taken from uninfected macaques and SIV-infected macaques with acute and 
chronic SIV infection and AIDS.  Cross-sectional comparisons between animals with chronic 
infection that lack disease and tissues taken from animals with AIDS will allow for a preliminary 
observation of differences in macrophages associated with disease status.   
 
Aim 2:  Determine whether prospective changes in gut and gut-draining lymph node 
macrophages differ in SIV-infected rhesus macaques that go on to develop progressive or 
controlled disease.  To expand on the cross-sectional study, I will design a longitudinal model 
of diverging disease courses based on viral set-point using differential expression of SIV 
controlling allele Mamu-B*008.  Here, small intestine and gut-draining mesenteric lymph nodes 
will be harvested prior to infection and then at weeks 2, 12, and 20 post infection for temporal 
assessment of changes in macrophage numbers, activation, death, and function with infection.  
Longitudinal assessment of macrophages in macaques that go on to develop controlled and 
progressive SIV infection will allow for determination of macrophage involvement in disease 
pathogenesis as well as whether changes in macrophages are either causally related to or are a 
consequence of disease outcome.    
 
Aim 3:  Determine whether the macrophage response in peripheral lymph nodes differs 
significantly from macrophages in mucosal tissues in controlled and progressive SIV 
infection.  To provide clarity on whether there are anatomical differences in macrophages role in 
HIV/AIDS pathogenesis, I will also investigate the macrophage response to infection in 
peripheral lymph nodes as it relates to changes in mucosal tissues using the model described in 
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Aim 2.  If we are to effectively intervene or augment macrophage activity for therapeutic 
purposes, it is imperative to understand whether changes in macrophages in response to SIV 
infection are uniform or differ across tissues.   
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3.0  CHAPTER ONE:  MACROPHAGE ACCUMULATION IN GUT MUCOSA 
DIFFERENTIATES AIDS FROM CHRONIC SIV INFECTION IN RHESUS 
MACAQUES 
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3.2 ABSTRACT 
The relationship between recruitment of mononuclear phagocytes to lymphoid and gut tissues 
and disease in HIV and SIV infection remains unclear.  To address this question, we conducted 
cross-sectional analyses of dendritic cell (DC) subsets and CD163+ macrophages in lymph nodes 
(LNs) and ileum of rhesus macaques with acute and chronic SIV infection and AIDS.  In LNs 
significant differences were only evident when comparing uninfected and AIDS groups, with 
loss of myeloid DCs and CD103+ DCs from peripheral and mesenteric LNs.  In contrast, there 
were fourfold more macrophages in ileum lamina propria in macaques with AIDS compared 
with chronic infection, and this increased to 40-fold in Peyer’s patches.  Gut macrophages 
exceeded plasmacytoid DCs and CD103+ DCs by ten- to 17-fold in monkeys with AIDS but 
were at similar low frequencies as DCs in chronic infection.  Gut macrophages in macaques with 
AIDS expressed IFN-α and TNF-α consistent with cell activation.  CD163+ macrophages also 
accumulated in gut mucosa in acute infection but lacked expression of IFN-α and TNF-α.  These 
data reveal a relationship between inflammatory macrophage accumulation in gut mucosa and 
disease and suggest a role for macrophages in AIDS pathogenesis.   
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3.3 INTRODUCTION 
Dendritic cells (DCs) and macrophages are mononuclear phagocytes that bridge innate and 
adaptive immunities while also contributing to pathogen control and inflammation.  In HIV 
infection of humans and SIV infection of Asian macaques, a loss of the two major DC subsets, 
myeloid DCs (mDCs) and plasmacytoid DCs (pDCs), from blood is negatively correlated with 
viral load and disease outcome [211-219].  This loss is driven by apoptosis and recruitment of 
DCs to lymph nodes (LNs) and gut mucosa, coincident with altered function and production of 
inflammatory cytokines [83, 84, 88, 101, 103, 219-223].  Chronic SIV infection of rhesus 
macaques is also associated with loss from intestinal mucosa of CD103+ DCs [92], an important 
DC subset that traffics from gut to mesenteric LNs and imprints gut homing on lymphocytes 
[224-226].  Loss of CD103+ DCs is thought to contribute to the loss of IL-17-producing 
lymphocytes from gut and damage to gastrointestinal mucosal integrity [92], factors that lead to 
microbial translocation [91, 227].  Collectively, these findings have led to a focus on DCs as 
potential contributors of immune activation that is a hallmark of AIDS [228-230]. 
Much less is understood about the mobilization and trafficking of macrophages in HIV 
and SIV infection and the potential contribution of macrophages to disease control or 
progression [231, 232].  Macrophages accumulate in inguinal and axillary LNs during acute SIV 
infection of rhesus macaques [101, 154], and increased monocyte turnover is correlated with 
progression to AIDS in this model [194, 195].  Macrophages are most abundant in health in 
intestinal tissues [233], and further accumulation of macrophages in the intestine is seen in 
untreated HIV infection of humans and SIV infection of rhesus macaques [89, 153].  Evidence 
also exists for intestinal production of macrophage-associated proinflammatory molecules and 
altered macrophage phagocytic function and responsiveness to LPS in HIV and SIV infection 
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[89, 153].  However, whether alteration in macrophage dynamics in SIV or HIV infection is 
beneficial or detrimental remains an open question, as there have been no studies to our 
knowledge evaluating macrophage dynamics across different stages of infection and disease. 
To address these gaps in our understanding, in this study we determined the frequency 
and turnover of macrophages and DC subsets in LNs and gut mucosa of rhesus macaques with 
acute and chronic SIV infection and AIDS.  Our data reveal relatively modest differences 
between cell types in LNs only in macaques with AIDS when compared with uninfected animals.  
In contrast, up to 40-fold more macrophages were present in intestinal mucosa in macaques with 
acute SIV infection and AIDS relative to macaques with chronic SIV infection lacking disease.  
Gut macrophages from animals with AIDS but not acute infection have evidence of an 
inflammatory function, consistent with a role in disease progression. 
3.4 RESULTS 
3.4.1 mDC loss and marked increases in cell turnover in peripheral LNs in macaques 
with AIDS 
To evaluate the impact of pathogenic SIV infection on macrophages and DC subsets in lymphoid 
and mucosal tissues, we conducted cross-sectional analyses using specimens from rhesus 
macaques infected with the biologic isolate SIVmac251 as part of previous studies [83, 102, 
219].  Tissues were harvested either at the acute stage of infection (week 2, n = 6), at the chronic 
stage of infection but without disease (range week 66 to 78, median week 71, n = 6), or from 
animals with rapid progression to AIDS (range week 11 to 43, median week 33, n = 8; Table 1).  
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Table 1.  Animal characteristics. 
Samples from SIV-infected macaques were compared to healthy SIV-naïve macaques (n = 8). 
We first analyzed mononuclear phagocytes in cell suspensions of inguinal, axillary, or popliteal 
LNs, which we collectively termed peripheral LNs.  To delineate mononuclear phagocytes we 
used established flow cytometry methods [101] gating on CD3/CD20(lineage)-MHC-II+CD163-
CD11c+CD123- cells for mDCs, lineage-MHC-II+CD163-CD11c-CD123+ cells for pDCs, and 
lineage-MHC-II+CD163+ cells for macrophages (Fig. 1A).  To determine changes in individual 
subsets independently, the frequency of DCs and macrophages were calculated as a proportion of 
all live cells, which was based on lack of fluorescence after exposure to an amine-reactive dye 
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(Fig. 1A).  Preliminary findings using peripheral LN samples from macaques with acute (week 2, 
n = 6) and chronic (week 20, n = 11) SIVmac251 infection showed that mDC, pDC, and 
macrophage frequencies determined in this manner are highly correlated to frequencies based on 
tissue weight (R = 0.8589, p < 0.0001; data not shown), indicating that changes in T and B 
lymphocytes over time do not erroneously affect DC and macrophage frequencies when based on 
total number of live cells.  In peripheral LNs only the frequency of mDCs differed significantly 
across conditions, with loss of mDCs in monkeys with AIDS relative to uninfected macaques.  
There was a trend toward loss of pDCs in chronic infection and an increase in macrophages in 
acute infection (Fig. 1B).  SIV infection was associated with marked differences in the 
proportion of each subset expressing Ki67, a marker of recent cell division [83].  The proportion 
of Ki67+ mDCs in peripheral LNs of monkeys with AIDS exceeded all other groups, and Ki67+ 
pDCs in monkeys with AIDS and acute infection were greater than in uninfected macaques.  The 
frequency of Ki67+ macrophages in peripheral LNs in chronic infection and AIDS was greater 
than that in uninfected and acutely infected macaques (Fig. 1C).  When comparing the frequency 
of each cell type at different stages of infection or disease, the proportion of macrophages 
exceeded pDCs only in acute infection (Fig. 1D).  Flow cytometry findings were supported by 
immunohistochemistry analysis showing evidence of a loss of mDCs and pDCs in chronically 
infected relative to uninfected tissues, and a relative abundance of macrophages in acute 
infection (Fig. 1E). 
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Figure 1.  mDCs are lost from peripheral LNs in macaques with AIDS. 
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(A) Representative flow cytometric analysis of peripheral LN single-cell suspensions showing gating strategy to 
define macrophages (Macs), mDCs, and pDCs after exclusion of dead cells by amine reactive dye labeling.  (B, C) 
The proportion of each mononuclear phagocyte population in the live cell fraction (B) and the proportion of each 
population expressing Ki67 (C) in peripheral LNs from uninfected (UI) macaques and macaques with acute and 
chronic SIV infection and AIDS.  (D) The proportion of cells in the live cell fraction of peripheral LNs that is 
mDCs, pDCs, or macrophages in acute and chronic SIV infection or AIDS.  (B-D) Each symbol represents an 
individual animal and horizontal bars represent means.  *p < 0.05, **p < 0.01, ***p < 0.001.  Statistical 
comparisons were done using (B, C) ANOVA followed by Bonferroni’s multiple-comparison test or (D) repeated-
measures ANOVA followed by Tukey’s range test.  (A-D) Data shown represent 11 independent experiments.  (E) 
Immunofluorescence of peripheral LN sections from uninfected (left) and SIV-infected (right) macaques labeled 
with Ab to CD1a, CD123, and CD163 to identify mDCs, pDCs, and macrophages, respectively.  SIV-infected 
sections were taken at chronic infection for mDCs, and at acute infection for pDCs and macrophages.  Blue staining 
in each section is nuclei labeled with Hoechst dye.  Original magnification = 400x.  Images shown are representative 
of five independent experiments.
3.4.2 pDCs and macrophages accumulate but CD103+ DCs are depleted in mesenteric 
LNs in monkeys with AIDS 
We next investigated the influence of SIV infection on DC and macrophage dynamics in 
mesenteric LNs that drain the gut mucosa using similar strategies.  In contrast to peripheral LNs, 
there was no change in the frequency of mDCs over the course of infection, whereas pDCs and 
macrophages both significantly increased in frequency in monkeys with AIDS relative to 
uninfected monkeys (Fig. 2A).  The frequency of Ki67+ mDCs and pDCs increased significantly 
in acute infection and AIDS, whereas the frequency of Ki67+ macrophages increased in chronic 
infection and AIDS (Fig. 2B).  We next evaluated CD103+ DCs, which were identified as a 
subset of CD11c+ mDCs.  CD103+ DCs constituted about 30% of mDCs prior to infection in 
mesenteric LNs but were absent from peripheral LNs (Fig. 2C and data not shown).  CD103+ 
DCs were lost from mesenteric LNs and the frequency of Ki67+ CD103+ DCs significantly 
increased in AIDS relative to uninfected animals (Fig. 2C).  The frequency of macrophages 
exceeded mDCs (with the CD103+ subset included) in acute infection and AIDS, and exceeded 
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pDCs in acute infection, but similar frequencies of each cell type were present in mesenteric LNs 
in chronic infection (Fig. 2D).  To support the flow cytometry findings, we performed 
immunohistochemistry of mesenteric LNs focusing on macrophages and CD103+ DCs, which 
were distinguished from T cells by lack of CD3 staining.  As expected, in situ staining revealed 
an increase in macrophages but a marked loss of CD103+ DCs as infection progressed (Fig. 2E). 
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Figure 2.  Loss of CD103+ DCs but accumulation of pDCs and macrophages in mesenteric LNs in macaques with AIDS.
(A, B) The proportion of each mononuclear phagocyte in the live cell fraction (A) and the proportion of each 
population expressing Ki67 (B) in mesenteric LNs from uninfected (UI) macaques and macaques with acute and 
chronic SIV infection and AIDS.  (C) Left: representative flow cytometric analysis of mesenteric LN single-cell 
suspensions showing gating to define the CD103+ fraction of mDC based on isotype control Ab (IgG) labeling. 
Right: the proportion of mDCs that is CD103+ and the proportion of these cells that express Ki67 in mesenteric LNs 
from uninfected (UI) macaques and macaques with acute and chronic SIV infection or AIDS.  (D) The proportion of 
cells in the live cell fraction of mesenteric LNs that is mDCs, pDCs, or macrophages (Macs) in acute and chronic 
SIV infection or AIDS.  (A-D) Each symbol represents an individual animal and horizontal bars represent means. 
*p < 0.05, **p < 0.01, ***p < 0.001.  Statistical comparisons were done using (A-C) ANOVA followed by 
Bonferroni’s multiple-comparison test or (D) repeated-measures ANOVA followed by Tukey’s range test.  Data 
shown represent 14 independent experiments.  (E) Immunofluorescence of mesenteric LN sections from uninfected 
macaques and macaques with acute SIV infection or AIDS labeled with Ab to CD163 to identify macrophages and 
CD3 and CD103 to identify CD103+CD3- DC (highlighted by arrowheads).  Blue staining in each section is nuclei 
labeled with Hoechst dye.  Original magnification = 400x.  Images shown are representative of five independent 
experiments.
3.4.3 Macrophages accumulate in gut mucosa in acute SIV infection and AIDS but not 
chronic infection 
Next we used immunofluorescence and confocal microscopy to detect mononuclear phagocytes 
in the ileum in a subset of macaques for which tissues were available.  We chose to image and 
quantify cells in situ to provide information on the local distribution within Peyer’s patches (an 
immune inductive site) and lamina propria (an immune effector site) and to avoid prolonged 
tissue processing associated with the generation of cell suspensions that may lead to unintended 
cell loss.  For mDCs, we focused on the CD103+ subset given the profound loss from mesenteric 
LNs.  CD103+ DCs in naïve macaques were primarily found in the subepithelial dome and T-
cell-rich interfollicular zones of Peyer’s patches and scattered throughout the lamina propria, and 
there was a trend toward loss of CD103+ DCs from lamina propria in monkeys with AIDS (Fig. 
3A).  CD123+ pDCs were infrequent in both lamina propria and Peyer’s patches of uninfected 
ileum and there was a nonsignificant trend toward accumulation of pDCs in lamina propria in 
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chronic infection and AIDS associated with considerable animal-to-animal variation (Fig. 3B).  
CD163+ macrophages were present at high frequencies relative to CD103+ DCs and pDCs prior 
to infection, most notably in lamina propria (Fig. 3C).  In marked contrast to DCs, the frequency 
of macrophages in gut mucosa differed significantly as a function of stage of infection and 
disease status.  Monkeys with acute infection and AIDS had significantly greater frequencies of 
macrophages in both lamina propria and Peyer’s patches than did monkeys with chronic 
infection lacking disease (Fig. 3C).  The frequency of macrophages in these compartments was 
10 to 20 times higher than CD103+ DCs and pDCs in acute infection and AIDS but did not differ 
from the DC subsets in chronically infected tissues (Fig. 3D).  The frequency of macrophages in 
gut mucosa did not correlate with peripheral CD4+ T-cell counts or plasma virus load (data not 
shown). 
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     Figure 3.  Accumulation of macrophages in gut mucosa in macaques with acute SIV infection 
 AIDS but not chronic infection.
(A-C) Top: immunofluorescence of ileum sections from uninfected macaques and macaques with acute 
SIV infection and AIDS stained with antibodies to CD103 and CD3 to identify CD103+CD3- DC (A), CD123 to 
identify pDC (B), and CD163 to identify macrophages (Macs, C) in lamina propria (LP) and Peyer’s 
patches (PP). Arrowheads highlight cells of interest.  Blue staining in each section is nuclei labeled with Hoechst 
dye.  Original magnification = 200x.  Images shown are representative of 12 independent experiments.  (Bottom) 
The frequency of each cell type per 500 nucleated cells enumerated using ImageJ and MetaMorph software.  (D) 
The proportion of cells in lamina propria and Peyer’s patches that is CD103+CD3- DCs, pDCs, or macrophages 
in acute and chronic SIV infection or AIDS.  (A-D) Each symbol represents an individual animal and horizontal 
bars represent means. The number of animals differs between lamina propria and Peyer’s patches as in some 
cases Peyer’s patches were 
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not identified.  *p < 0.05, **p < 0.01, ***p < 0.001.  Statistical comparisons were done using (A-C) ANOVA 
followed by Bonferroni’s multiple-comparison test or (D) repeated-measures ANOVA followed by Tukey’s range 
test. 
3.4.4 Evidence for inflammatory macrophages in gut mucosa of monkeys with AIDS 
To address whether the macrophages that accumulate in gut mucosa in acute infection and AIDS 
may contribute to the inflammatory response, we performed in situ staining for CD163 along 
with proinflammatory cytokines IFN-α and TNF-α.  In both uninfected and chronically infected 
tissues small numbers of cells expressing IFN-α but not TNF-α were detected, but in both cases 
cytokine staining did not localize with macrophages.  Negligible staining for either cytokine was 
detected in acutely infected tissues, despite macrophage accumulation (Fig. 4).  In contrast, a 
substantial number of macrophages present in gut mucosa of macaques with AIDS expressed 
IFN-α and TNF-α, consistent with an inflammatory function, and expression of these cytokines 
appeared to be restricted to macrophages. 
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Figure 4.  Gut macrophages from macaques with AIDS but not acute infection express IFN-α and TNF-α. 
(A and B) Representative immunofluorescence of ileum sections from uninfected macaques and macaques with 
acute and chronic SIV infection and AIDS labeled with Ab to CD163 to identify macrophages and Ab to IFN-α (A) 
and TNF-α (B).  Blue staining in each section is nuclei labeled with Hoechst dye.  Original magnification = 400x.  
Images shown are representative of 12 independent experiments. 
 
3.5 DISCUSSION 
This is the first report to our knowledge to provide a detailed comparative analysis of 
mononuclear phagocyte subsets in lymphoid and mucosal tissues across different stages of SIV 
infection and disease.  Significant differences existed between DCs and macrophages in 
peripheral and mesenteric LNs when comparing uninfected macaques and macaques with AIDS, 
consistent with earlier reports [103, 234].  However, only the frequency of macrophages in gut 
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mucosa distinguished macaques with AIDS from those with chronic SIV infection lacking 
disease.  Even with the relatively small number of animals studied this effect was striking, with a 
fourfold difference in mean macrophage frequency in lamina propria and a 40-fold difference in 
mean macrophage frequency in Peyer’s patches of macaques with AIDS compared with chronic 
infection.  These data indicate that accumulation of macrophages in gut mucosa correlates with 
disease and suggest a role for macrophages in AIDS pathogenesis.   
Macrophages are abundant in intestinal mucosa in health and are important in 
maintaining a noninflammatory environment and normal tissue homeostasis [116, 233].  In 
contrast, our findings indicate that CD163+ macrophages accumulating in the gut of macaques 
with AIDS express TNF-α and IFN-α, consistent with an inflammatory function, and data from 
untreated HIV-infected patients reveal secretion of a number of macrophage-related 
proinflammatory molecules in gut mucosa [89].  Similarly, in inflammatory bowel disease and 
ulcerative colitis, activated macrophages producing proinflammatory cytokines including TNF-α 
infiltrate the bowel and contribute to an inappropriate innate response [235-237].  Macrophage 
production of TNF-α may directly affect the integrity of gut epithelium by inducing epithelial 
cell apoptosis and disrupting intracellular tight junctions [132, 238], and gut macrophages in 
HIV infected-individuals have reduced capacity to phagocytose bacteria that may transit the 
damaged epithelium [89].  Collectively, these findings suggest a potential contribution of 
macrophages to gut inflammation and microbial translocation in AIDS. 
It is notable that CD163+ macrophages also accumulated in gut mucosa in acutely 
infected macaques but lacked production of IFN-α and TNF-α, suggesting they may be 
functionally distinct from gut macrophages in AIDS.  A key function of macrophages is antigen 
presentation, and CD163+ macrophages in SIV-infected LNs lose capacity to stimulate CD4+ T 
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cells [100].  It will be important to assess antigen-presenting function of gut macrophages at 
different stages of SIV infection, particularly as they accumulate heavily in Peyer’s patches, an 
immune inductive site. 
Previous studies have revealed loss of CD103+ DCs from both gut mucosa and 
mesenteric LNs in rhesus macaques infected with SIV for more than 90 days, although 
distinction was not made between animals with and without disease [92].  In our study with 
similar numbers of animals, we found significant depletion of CD103+ DCs from mesenteric 
LNs in macaques with AIDS but not chronic SIV infection relative to uninfected macaques, 
suggesting that CD103+ DC depletion is a function of disease.  CD103+ DCs that migrate from 
gut mucosa to mesenteric LNs produce retinoic acid from dietary vitamin A that in turn drive 
development and maintenance of IL-17- and IL-12-producing cells and Treg [226, 239, 240].  
IL-17 is associated with maintenance of epithelial integrity, and loss of Th17 cells in acute 
pathogenic SIV infection correlates with mucosal immune dysfunction and is predictive of 
systemic immune activation [241, 242].  There is also evidence that Treg are depleted from 
intestinal lamina propria but not blood or LNs in acute SIV infection [243].  The loss of CD103+ 
DCs from mesenteric LNs could, therefore, indirectly impact chronic immune activation and 
together with macrophage accumulation in gut mucosa could promote microbial translocation 
through Th17-mediated loss of epithelial integrity.   
Accumulation of pDCs in colorectum and ileum of macaques with chronic SIV infection 
has been noted previously, with frequencies roughly fourfold greater than in uninfected samples, 
although there was no comparison done between animals with chronic infection and AIDS [88, 
222].  In our study there was a trend toward increased frequency of pDCs in lamina propria of 
macaques with chronic infection relative to uninfected animals, but no detectable differences in 
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pDC frequency when comparing chronic infection and AIDS.  Moreover, macrophages were 
tenfold more numerous in lamina propria and 17-fold more numerous in Peyer’s patches in AIDS 
monkeys compared with pDCs, whereas the frequency of both pDCs and macrophages was low 
and indistinguishable in chronic infection, reflecting a far greater accumulation of gut 
macrophages than pDCs in disease. 
Both DCs and macrophages appear to have dysregulation of pro- and antiapoptotic 
molecules that favors apoptosis in SIV and HIV infection [244], and apoptotic DCs and 
macrophages can readily by identified in LNs of SIV-infected macaques [83, 103, 195, 220].  
Despite relatively minor changes in frequency of mononuclear phagocytes in LNs over the 
course of infection our findings reveal an underlying strong regenerative response with marked 
increases in Ki67 expression, consistent with previous findings of BrdU incorporation in vivo 
[83, 101, 195].  These data suggest an increase in cell turnover within LNs, with increased death 
of cells being offset by increased recruitment of DCs and monocytes from blood.   
Our study showed distinct production of IFN-α in gut mucosa in uninfected animals that 
may serve to protect the mucosa from viral invasion.  The source of IFN-α remains to be 
determined, but constitutive expression of other type I IFN including IFN-ε by intestinal 
epithelial cells is known to occur in gut mucosa of SIV-naïve macaques [245].  Our findings 
provide further support for the notion that pDCs are not the exclusive producers of IFN-α in 
tissues during SIV and HIV infection, and that other cells including macrophages, lymphocytes, 
and mDCs can contribute significantly to this response [102, 246].  The data suggest that focus 
should be directed toward macrophages and their potential contribution to the inflammatory 
response associated with chronic immune activation during AIDS, particularly in the gut 
mucosal environment.   
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3.6 MATERIALS AND METHODS 
3.6.1 Animals and tissues 
Indian-origin rhesus macaques housed at the University of Pittsburgh (U.S. Public Health 
Service Assurance Number:  A3187-01) were used in this study and all animal manipulations 
and procedures were done with appropriate institutional regulatory oversight and approval.  
Macaques were infected with SIVmac251 as part of previously published studies [83, 102, 219].  
Tissues were harvested either at the acute stage (week 2, n = 6) or chronic stage of infection 
(range week 66 to 78, median week 71, n = 6), or during AIDS (range week 11 to 43, median 
week 33, n = 8; Table 1).  Samples from eight uninfected, healthy macaques were used as 
controls.  Not all animals were used in all analyses depending on availability of tissues.  To 
generate LN suspensions, freshly harvested LNs were digested using 1 mg/mL collagenase D 
(Sigma-Aldrich) and 20 µg/mL DNAse I (Roche) in RPMI 1640 medium with 2% FBS and 10 
mmol HEPES and cryopreserved for later use.  To generate tissue sections for 
immunohistochemistry, harvested tissues were fixed in 2% paraformaldehyde for 2 h at 4°C and 
the infused with 30% sucrose overnight.  Tissues were frozen with an aerosol of 
chlorodifluoromethane (Histofreeze 22, Fischer Scientific).   
3.6.2 Flow cytometry 
LN single-cell suspensions were stained with the following cross-reactive surface-labeling anti-
human antibodies for mononuclear phagocyte detection (all antibodies were purchased from BD 
Biosciences unless otherwise noted):  CD11c (clone S-HCL-3), CD123 (7G3), CD103 (2G5, 
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Beckman Coulter), CD163 (GH1/61, BioLegend), HLA-DR (L243), CD20 (2H7, eBioscience), 
and CD3 (SP34-2).  Nonviable cells were excluded by staining with a fluorescent LIVE/DEAD 
cell stain (Invitrogen).  For analysis of nuclear protein Ki67 (B56), LN cells were permeabilized 
with Cytofix/Cytoperm (BD Biosciences) and then stained with Ab in Perm/Wash buffer (BD 
Biosciences).  Data were acquired using an LSR II flow cytometer (BD Biosciences) and 
analyzed using FlowJo 7.6.4. 
3.6.3 Immunofluorescence microscopy 
LN and ileum sections were hydrated in PBS on Superfrost Plus glass slides and then blocked for 
1 h with 10% serum matching the species of the secondary Ab.  Endogenous peroxidase was 
quenched using 0.15% hydrogen peroxide.  Sections were incubated for 1.5 h with antibodies to 
CD163 (GH1/61, eBioscience), CD123 (7G3), CD1a (SK9, BioLegend), CD3 (polyclonal, 
DAKO), and/or CD103 (2G5.1, AbD Serotec).  The remaining steps were conducted in 
accordance with the standard tyramide signal amplification kit protocol (Invitrogen).  To detect 
cytokine expression, sections were incubated with Ab to IFN-α (MMHA2, PBL Interferon 
Source) or TNF-α (Mab11) overnight and developed using goat-anti-mouse-HRP AlexaFluor 
546 with tyramide amplification.  Sections were costained using biotinylated mouse Ab to 
CD163 followed by mouse HRP-streptavidin AlexaFluor 488.  All staining included an 
appropriately concentrated isotype-matched Ab.  Cell nuclei were identified using membrane 
permeable Hoescht dye.  Slides were mounted in gelvatol mounting medium and viewed on an 
Olympus Fluoview 1000 confocal microscope.  For quantification of cells in gut mucosa, an 
average of seven nonoverlapping regions of lamina propria and at least three entire Peyer’s 
patches were imaged.  Cells of interest were enumerated manually using ImageJ software (U.S. 
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National Institutes of Health) and the total number of nuclei per image was determined digitally 
using MetaMorph Software (Molecular Devices).  Cell frequencies were then calculated using 
the formula:  (total number of cells of interest x 5000) / total number of nuclei. 
3.6.4 Statistical analysis 
Cross-sectional comparisons between uninfected and infected groups were performed using a 
one-way ANOVA followed by Bonferroni’s multiple-comparison test.  Comparisons made 
between cell types within the same animal were done using repeated-measures ANOVA 
followed by a Tukey’s range test.  All statistical tests were performed using GraphPad Prism 
version 5.  A p-value < 0.05 was considered significant.   
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4.0  CHAPTER TWO:  GUT MACROPHAGE ACCUMULATION AND 
PHAGOCYTIC DYSFUNCTION IS PREDICTIVE OF PROGRESSIVE DISEASE IN 
SIV-INFECTED RHESUS MACAQUES 
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4.2 ABSTRACT 
The gastrointestinal tract is a major site of inflammation and macrophage accumulation in HIV-
infected humans and SIV-infected rhesus macaques, however macrophage contribution to 
disease progression remains unclear.  To address this issue, we prospectively studied 
macrophages in gut and gut-draining mesenteric lymph nodes (LNs) from SIV-infected 
macaques with dichotomous expression of controlling MHC class I alleles that were predicted to 
be SIV controllers or progressors based on diverging set-point virus loads.  Infection induced a 
massive accumulation of CD163+ macrophages into gut mucosa in the acute phase which 
persisted into chronic infection in SIV progressors but was resolved in controllers.  Sustained gut 
macrophage accumulation was associated with the level of CD163 expression on α4β7+CD16+ 
blood monocytes and was correlated with the extent of epithelial damage.  Macrophages isolated 
from intestine of SIV progressors in chronic infection had reduced phagocytic function relative 
to SIV controllers and uninfected macaques, and the proportion of phagocytic macrophages in 
gut negatively correlated with gut macrophage density, epithelial breach, and plasma but not 
tissue virus burden.  Macrophages in intestine produced low levels of cytokines regardless of 
disease course, while mesenteric LN macrophages from SIV progressors became increasingly 
responsive to stimulation as infection advanced.  These data indicate that CD163+ macrophages 
accumulate in gut mucosa early in progressive SIV infection in response to sustained intestinal 
damage but fail to adequately phagocytose debris, potentially establishing a positive feedback 
loop promoting recruitment.  The non-inflammatory function of gut macrophages may serve to 
limit inflammation early in infection.   
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4.3 INTRODUCTION 
Macrophages are mononuclear phagocytes that mediate innate homeostatic and inflammatory 
functions in tissues throughout the body.  Macrophages are most abundant in the gastrointestinal 
tract, where they maintain a non-inflammatory environment, expressing low levels of innate 
response receptors and primarily scavenging debris and promoting wound repair [115, 116, 144, 
247].  Under inflammatory conditions, such as with Crohn’s disease and ulcerative colitis, 
colonic tissues have an increased frequency of activated proinflammatory macrophages that are 
hyper-responsive to bacterial stimuli and correlate with increased turnover of CD14-high 
inflammatory monocytes [132, 248-251].  These findings have implications for macrophage 
recruitment and accumulation as a central mechanism in the pathogenesis of inflammatory bowel 
disorders [252].  Macrophages also infiltrate the intestine in HIV-infected humans and SIV-
infected macaques [89, 150, 196].  However, whether macrophage accumulation in intestine 
reflects a beneficial or detrimental role in HIV/SIV pathogenesis remains unknown. 
 Comparative studies between natural SIV hosts that have a nonpathogenic disease course, 
such as the sooty mangabey and African green monkey, and macaques that generally progress to 
AIDS have improved our understanding of intestinal biology in HIV/SIV pathogenesis [71], but 
interpretation of findings are complicated by inherent differences between the species.  Similarly, 
comparative studies in rhesus macaques infected with pathogenic and attenuated strains of SIV 
are highly informative but are limited by differences in virus replication capacity and persistence 
[253].  In HIV infection, viral set-point is used as a predictive measure of disease prognosis and 
set-point plasma virus loads above 104 RNA copies/mL are statistically correlated with an 
increase in AIDS-related morbidity [34, 35].  The rhesus macaque MHC class I allele Mamu-
B*008 is correlated with long-term control of SIV replication, generating CD8+ T cell responses 
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against comparable peptides as the human elite controlling allele HLA-B*27 [26, 49, 254].  
Macaque controlling alleles Mamu-A*001 and Mamu-B*017 are also associated with a low set-
point viral load, whereas rhesus macaques that lack expression of all 3 controlling alleles have 
high set-point virus loads and progress to disease in a predictable fashion [38, 255, 256].  By 
using SIV-infected rhesus macaques with or without expression of protective MHC class I 
alleles, immune responses in animals predicted to control or progress to disease based on viral 
set-point can be examined in the same species of monkey infected with the same strain of virus.  
In this study, we used differential expression of SIV controlling alleles to explore the potential 
contribution of gut macrophages early in infection to disease progression or control. 
 Our results reveal that CD163+ macrophages accumulate in gut mucosa early in 
progressive SIV infection in association with intestinal damage, but have reduced phagocytic 
capacity and fail to clear debris, providing a positive feedback for sustained macrophage 
recruitment.  The findings also reveal that gut macrophages in both SIV progressors and 
controllers, in contrast to macrophages in mesenteric lymph nodes (LNs), do not spontaneously 
release proinflammatory cytokines in chronic infection and do not respond to viral stimuli ex 
vivo.  These findings suggest that gut macrophages may serve to limit the inflammatory response 
early in progressive infection rather than promote it.   
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4.4 RESULTS 
4.4.1 SIV infection induces a persistent accumulation of CD163+ macrophages in small 
intestine in macaques with progressive infection 
To investigate the role of intestinal macrophages in SIV pathogenesis, we developed a model of 
diverging disease course using differential expression of protective MHC molecule Mamu-B*008 
[26].  We elected to use Mamu-B*008 over other SIV controlling alleles because fewer than 50% 
of SIVmac-infected macaques expressing Mamu-B*008 develop escape mutants compared to 
nearly 75% of primates expressing A*001 or B*017 [26, 254, 257].  We identified 12 rhesus 
macaques with and 12 without expression of Mamu-B*008 based on a pre-study haplotype 
screen.  Of the 12 that expressed Mamu-B*008, 3 co-expressed controller allele Mamu-A*001 
and 1 animal expressed alleles Mamu-B*008, A*001, and B*017 (Table 2).  Mamu-B*008-
negative macaques also lacked expression for Mamu-A*001 and Mamu-B*017.  Macaques were 
inoculated intrarectally with a single high dose (105 TCID50) of pathogenic isolate SIVmac251 
and monitored out to week 20 post-infection.  A threshold of 104 SIV RNA copies/mL plasma at 
virus load set-point (week 8) was used to sort animals into predicted SIV progressors or 
controllers based on evidence that SIVmac escape mutants occur within the first 8 weeks of 
infection [49].  In total, 14 macaques had set-point virus loads >104 SIV RNA copies/mL and 
were defined as SIV progressors and 10 had set-point virus loads <104 SIV RNA copies/mL and 
were defined as SIV controllers (Table 2).  Viral load divergence in the two groups was 
statistically significantly by week 3 post-inoculation (Fig. 5A).   
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Table 2.  Animal characteristics. 
 
 
Using these 2 groups, we first evaluated the frequency of macrophages in intestine using 
established in situ techniques [102, 150].  To do this, sections of small intestine harvested prior 
to infection and at weeks 2, 12, and 20 post-infection were stained with fluorescent antibodies to 
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CD163 for macrophage identification and then quantified relative to the number of cell nuclei 
present.  In parallel, we identified and analyzed macrophage frequency in mesenteric LNs using 
previously published flow cytometry methods, gating on CD3/CD20-MHC-II+CD163+ cells 
[150].  The density of CD163+ macrophages increased over 2-fold in both the mesenteric LNs 
and gut mucosa in acute SIV infection compared with pre-infection (Fig. 5B, C).  By week 12, 
the proportion of macrophages in mesenteric LNs had declined to pre-infection levels, however 
in gut there was a stark divergence in macrophage abundance between controllers, which had 
declined in numbers, and progressors, which was sustained in numbers, that achieved statistical 
significance at week 20 (Fig. 5B, D).  Spearman analysis revealed that gut macrophage 
frequency at weeks 12 and 20 strongly correlated with the level of chronic phase plasma viremia 
(Fig. 5C) 
To determine if monocyte trafficking represented a potential mechanism for increased 
macrophages in SIV-infected intestine, we stained PBMC for CD14 and CD16 to delineate the 
three monocyte subsets found in blood and assessed for expression of gut-homing integrin α4β7 
by flow cytometry (Fig. 5E).  Monocytes were identified as CD16-CD14+, CD16+CD14+, or 
CD16+CD14- within the MHC-II+ population lacking expression for CD3, CD20, and CD8 as 
described previously [258].  In the absence of SIV, all monocyte subsets expressed low levels of 
α4β7.  After infection, both SIV controllers and progressors had an increased frequency of 
α4β7+ monocytes regardless of subset at week 2 post-infection that declined by chronic infection 
and was not significant between groups (Fig. 5F).  To evaluate if gut-homing monocytes could 
be a source of accumulating CD163+ macrophages, we next looked at expression of CD163 on 
α4β7+ monocytes.  Consistent with previous reports, the CD16+CD14- subset expressed the 
lowest level of CD163 in SIV-naïve blood, whereas expression of CD163 on CD16+CD14+ and 
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CD16-CD14+ monocytes was nearly 5-fold higher by comparison [259].  Notably, CD163 
expression was selectively elevated on all α4β7+ monocytes in macaques with progressive SIV 
infection during the acute phase compared to controllers and remained elevated at week 12 only 
on the CD16+CD14- subset (Fig. 5G). 
 
Figure 5.  Relationship between plasma viral burden and CD163+ macrophage frequency in SIV-infected 
small intestine. 
(A) Longitudinal viral RNA burden in plasma (n = 24).  Red depicts macaques with week 8 viral loads >104 RNA 
copies/mL (SIV progressors) and blue depicts macaques with week 8 viral loads <104 RNA copies/mL (SIV 
controllers).  (B) The proportion of CD163+ macrophages in mesenteric LNs as determined by flow cytometry.  (C) 
(Left) The frequency of intestinal CD163+ macrophages enumerated using ImageJ and MetaMorph software.  
(Right) Correlation between the number of intestinal CD163+ macrophages and plasma viral loads at weeks 12 and 
20.  (D) Representative immunofluorescence of small intestine sections from macaques prior to infection and at 
weeks 2, 12, and 20 post-infection stained with antibodies to CD163 to identify macrophages.  Original 
magnification = 200x.  (E) Representative flow cytometric analysis of PBMC showing gating to define 
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CD16+CD14-, CD16+CD14+, and CD16-CD14+ monocytes and monocytes expressing α4β7.  (F) The proportion 
of each monocyte subset expressing α4β7.  (G) Median fluorescence intensity of CD163 on each subset of α4β7+ 
monocytes.  Horizontal lines in (B) and (C) represent medians.  # signifies cross-sectional differences between 
progressors and controllers and * signifies longitudinal differences within the same groups.  For (A) statistical 
comparisons were done using a two-tailed nonparametric Mann-Whitney U test.  For (B), (F), and (G) statistical 
comparisons were done using a regular two-way ANOVA followed by Sidak’s post test (#) or nonparametric one-
way ANOVA followed by Dunn’s post test (*).  Correlations in (C) were determined using a two-tailed 
nonparametric Spearman rank test.  Black asterisks reflect all animals.  */# p < 0.05; **/## p < 0.01; ***/### p < 
0.001.  
 
4.4.2 Progressive SIV infection is associated with increased intestinal pathology and 
microbial translocation 
We next sought to investigate the relationship between CD163+ macrophage frequency and 
hallmarks of SIV pathogenesis in the gut, namely damage to the intestinal epithelial barrier and 
microbial translocation [90].  Sections of small intestine were stained with antibodies to 
cytokeratin to assess intestinal epithelial integrity and antibodies to E.coli to assess microbial 
translocation by immunohistochemistry as previously published [90].  Confocal microscopy 
revealed that tissues taken prior to infection displayed uniform staining for cytokeratin along the 
interface of the lumen and lamina propria reflecting an uncompromised barrier of columnar 
epithelial cells (Fig. 6A).  Qualitative and quantitative analysis revealed a pronounced disruption 
of cytokeratin expression by weeks 12 and 20 in SIV progressors that was not apparent in 
macaques with controlled infection (Fig. 6A, B).  Evidence of microbial translocation as 
measured by E.coli staining was sparse in the intestinal lamina propria prior to infection, with the 
majority of E.coli present on the luminal side of the gut (Fig. 6A).  Infection was associated with 
a statistically significant increase in percent lamina propria occupied by E.coli, primarily among 
SIV progressors, however there was considerable variation between animals (Fig. 6B).  
Increased intestinal damage in chronic infection strongly correlated with macrophage abundance 
and chronic phase viremia, but not microbial translocation (Fig. 6C). 
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Figure 6.  Increased intestinal pathology and microbial translocation is associated with progressive SIV 
infection. 
(A) Representative immunofluorescence of small intestine sections from macaques taken prior to infection and at 
weeks 2, 12, and 20 post-infection stained with antibodies to cytokeratin (Top) or E.coli (Bottom) to identify 
epithelial integrity and extent of microbial translocation.  Original magnification = 200x.  (B) Quantitative image 
analysis showing ratio of breach to intact intestinal epithelium determined by cytokeratin+ staining (Left) and 
percentage of lamina propria occupied by E.coli+ staining (Right).  Quantitative of cytokeratin+ staining and E.coli+ 
staining was carried out using NIS-Elements software.  Horizontal lines in (B) represent medians.  # signifies cross-
sectional differences between progressors and controllers and * signifies longitudinal differences within the same 
groups.  Statistical comparisons were done using a regular two-way ANOVA followed by Sidak’s post test (#) or 
nonparametric one-way ANOVA followed by Dunn’s post test (*).  (C) Correlation between the ratio of breach to 
intact intestinal epithelium and the number of intestinal CD163+ macrophages, the percentage of lamina propria 
occupied by E.coli and the number of intestinal CD163+ macrophages, the ratio of breach to intact intestinal 
epithelium and the percentage of lamina propria occupied by E.coli, and ratio of breach to intact intestinal 
epithelium and plasma viral load at weeks 12 and 20.  Correlations were determined using a two-tailed 
nonparametric Spearman rank test.  Black asterisks reflect all animals.  Red depicts SIV progressors and blue depicts 
SIV controllers.  */# p < 0.05; **/## p < 0.01; ***/### p < 0.001. 
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4.4.3 Intestinal CD163+ macrophages have impaired phagocytic function in macaques 
with progressive SIV infection 
Next we used confocal microscopy to analyze in situ whether accumulating macrophages 
phagocytose cellular and bacterial debris in small intestine.  Sections of intestine were stained 
with antibodies to CD163 and either cytokeratin, E.coli, or hemoglobin, the biological ligand for 
CD163, and then analyzed for co-expression, a measure of macrophage phagocytosis (Fig. 7A).  
Staining for cytokeratin in infected gut, particularly in regions with intestinal breach, revealed 
cytokeratin+ debris within the lamina propria where large clusters of macrophages could also be 
found.  Co-staining for CD163 and lamina propria-associated cytokeratin could be detected in 
infected tissues (Fig. 7A, top).  In contrast, co-localization of CD163 with E.coli+ staining was 
rare in both uninfected and infected intestine, even in tissues where microbial translocation was 
most abundant (Fig. 7A, middle).  Hemoglobin staining was plentiful in infected intestine, 
suggestive of focal hemorrhage and hemolysis, and confocal imaging revealed hemoglobin 
deposits within CD163+ macrophages (Fig. 7A, bottom). 
 To quantitatively address the impact of SIV infection on macrophage phagocytic 
function, we next assessed the ability of isolated gut macrophages to engulf antigen ex vivo.  
Phagocytosis was determined by measuring real-time uptake of fluorescently-labeled bioparticles 
using a pH-sensitive assay.  Intestinal suspensions from before infection and at week 20 post-
infection were incubated with bioparticles and then stained with antibodies for detection of 
phagocytic macrophages by flow cytometry.  Macrophages were delineated in suspension by 
gating CD45+CD3/CD20-MHC-II+CD163+ cells and phagocytic macrophages identified as 
pHrodo+ (Fig. 7B).  We also analyzed bioparticle uptake in macrophages from mesenteric LNs 
for comparison.  Phagocytic macrophages in gut represented a median 27% of the total CD163+ 
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population prior to infection, and roughly twice as many macrophages were able to uptake 
antigen in mesenteric LNs (Fig. 7C).  After infection, however, we found a dramatic decline in 
bioparticle uptake by intestinal macrophages at week 20 in SIV progressors compared to 
macrophages in SIV controllers and uninfected macaques.  In contrast, we found no change in 
mesenteric LN macrophage’s ability to phagocytose bioparticles with infection and no 
differences between groups (Fig. 7C).  The frequency of phagocytic macrophages in gut mucosa 
inversely correlated with gut macrophage abundance, intestinal breach, and chronic phase viral 
burden (Fig. 7D). 
 To determine whether a decline in phagocytic function could be related to the presence of 
virus in tissues and/or direct viral infection, we next quantified cell-associated virus in 
mesenteric LNs and intestine by RT-PCR as well as determined the percentage of SIV p27 
(gag)+ macrophages in suspension by flow cytometry.  In both mesenteric LNs and gut, there 
was a nonsignificant trend towards more cell-associated virus in progressors compared to 
controllers at week 20 (Fig. 7E).  Interestingly, virus in mesenteric LNs tended to be more 
prevalent per 1x106 cells than in small intestine.  Flow cytometric assessment of p27+ cells 
revealed infected T cells in mesenteric LN and intestinal suspensions, however p27+ 
macrophages were rare at both sites at week 20 post-infection (Fig. 7F). 
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Figure 7.  Intestinal CD163+ macrophages from macaques with progressive SIV infection have impaired 
phagocytic function. 
(A) Representative immunofluorescence of small intestine sections from SIV-infected macaques stained with 
antibodies to CD163 and either cytokeratin to identify cytokeratin+ macrophages (Top), E.coli to identify E.coli+ 
macrophages (Middle), or hemoglobin to identify hemoglobin+ macrophages (Bottom).  LP = lamina propria and L 
= lumen.  (B) (Left) Representative flow cytometric staining in small intestine single-cell suspensions showing 
detection of CD163+ macrophages.  (Right) Representative flow cytometric staining for pHrodo on CD163+ 
macrophages in small intestine at pre-infection and at week 20 in high and low viral load samples.  (C) Quantitation 
 57 
of pHrodo+ macrophages in mesenteric LNs (Left) and small intestine (Right) analyzed by flow cytometry at pre-
infection and at week 20 in progressors and controllers.  Statistical comparisons were done using two-tailed 
nonparametric Mann-Whitney U test.  (D) Correlations between the percentage of pHrodo+ intestinal macrophages 
and (Left) the number of CD163+ macrophages per nucleated cells, (Middle) the ratio of breach to intact intestinal 
epithelium, and (Right) the plasma viral loads at week 20.  Correlations were determined using a two-tailed 
nonparametric Spearman rank test.  (E) Quantitation of cell-associated viral RNA in mesenteric LNs and small 
intestine at week 20.  Horizontal bars in (C) and (E) represent medians.  (F) Representative flow cytometric analysis 
of SIV-infected mesenteric LNs (Left) and small intestine (Right) at week 20 showing staining for SIV p27 in CD3+ 
T cells and CD163+ macrophages.  Black asterisks reflect all animals.  Red depicts SIV progressors and blue depicts 
SIV controllers.  */# p < 0.05; **/## p < 0.01; ***/### p < 0.001. 
   
4.4.4 Intestinal CD163+ macrophages do not spontaneously produce inflammatory 
cytokines and are non-responsive to viral stimulation before and after SIV infection 
We next evaluated whether increased macrophages in SIV-infected gut mucosa may contribute 
to gut-associated inflammation.  To address this question, we assessed the capacity of CD163+ 
macrophages in suspension to respond to ex vivo stimulation with aldrithiol-2-inactivated SIV 
(iSIV) that activates macrophages through TLR8, and influenza virus, which can stimulate RIG-I 
and TLR3, 7, and 8 [260-262].  We also stimulated macrophages with Env976, a uridine rich 
ssRNA oligonucleotide sequence derived from SIVmac251 env gene that induces macrophages 
from SIV-naïve peripheral LNs to produce IFN-α and TNF-α through TLR8 (Fig. 8A) [101].  In 
naïve mesenteric LNs, macrophages were moderately responsive to Env976 and iSIV 
stimulations but not influenza and produced low levels of cytokines spontaneously (Fig. 8B).  
After infection, there was a nonsignificant increase in the frequency of macrophages 
spontaneously producing cytokines that was sustained into chronic infection.  Similar changes in 
cytokine+ macrophages were seen after ex vivo stimulation during the acute stage, however the 
proportions were comparable to the level of cytokines produced spontaneously.  By week 20 
post-infection, macrophages from progressors were significantly more responsive to Env976 and 
iSIV compared to controllers (Fig. 8B).  In comparison, in gut mucosa, the percentage of 
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unstimulated or stimulated gut macrophages producing combinations of TNF-α, IFN-α, and/or 
IL-6 was below 5% in SIV-naïve macaques (Fig. 8C).  SIV progressors exposed to Env976 had 
significantly more cytokine+ macrophages at week 12 compared to pre-infection and week 2; a 
finding not observed in macrophages from animals with low set-point viral loads.  Nevertheless, 
differences in gut were minor, especially compared to mesenteric LNs, and overall very few 
intestinal macrophages produced any combination of TNF-α, IFN-α, or IL-6 spontaneously or in 
response to iSIV or influenza after infection regardless of predicted disease outcome (Fig. 8C). 
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Figure 8.  Intestinal CD163+ macrophages are non-inflammatory and non-responsive to viral stimulation in 
SIV infection. 
(A) Representative flow cytometric staining for CD163+ macrophages producing TNF-α, IL-6, and IFN-α in 
Env976 stimulated mesenteric LN single-cell suspensions.  (B, C) SPICE analysis of the proportion of mesenteric 
LN (B) and intestinal (C) CD163+ macrophages producing different permutations of TNF-α, IL-6, and IFN-α prior 
to infection and at weeks 2, 12, and 20 post-infection either spontaneously or after stimulation by Env976, influenza, 
or iSIV.  Statistical comparisons were done using a permutation test performed with SPICE software.  # signifies 
cross-sectional differences between progressors and controllers and * signifies longitudinal differences within the 
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same groups.  Red asterisks reflect SIV progressors and blue asterisks reflect SIV controllers.  */# p < 0.05; **/## p 
< 0.01; ***/### p < 0.001. 
 
4.5 DISCUSSION 
In this study, we report differences in macrophage abundance in gut mucosa of SIV-infected 
rhesus macaques that exist at the early stages of chronic infection and are correlated with plasma 
virus burden and degree of damage to gut epithelium.  In contrast to macrophages that dominate 
colon in inflammatory bowel disease, however, we found no evidence of a corresponding 
proinflammatory response from infiltrating macrophages in SIV-infected animals with increased 
enterocyte loss [132, 248, 250, 263].  Instead, gut macrophages in SIV infection were non-
responsive to viral agonists and had decreased phagocytic capacity in SIV progressors but not 
controllers.  These results suggest that increased intestinal pathology in animals with a 
progressive disease course is a mechanism of recruitment for macrophages into gut, and that 
macrophage phagocytic impairment may lead to continued recruitment in a positive feedback 
loop.   
It is not clear what role viral burden plays in mediating macrophage infiltration to tissues.  
Although there was a nonsignificant trend towards more cell-associated virus in gut in SIV 
progressors as compared to controllers, this could be related to the small sample size of our 
controller group, as others have reported a strong correlation between plasma viral load and viral 
replication in intestine [264].  Interestingly, CD163+ macrophages also accumulate in macaques 
with experimentally-induced colitis that lack SIV, suggesting factors other than virus contribute 
to recruitment, such as inflammation [265].  SIV-infected macaques administered an anti-TNF-α 
therapy had reduced CD163+ macrophage infiltration of peripheral LNs compared to treatment 
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controls, despite no change in plasma viremia and peripheral blood or lymph node T cell 
activation [190]. 
Currently the cause of intestinal macrophage dysfunction in animals with progressive 
SIV infection is unclear but likely to be multifactorial.  Macrophages are secondary reservoirs of 
HIV/SIV in the gastrointestinal tract and support infection and active replication of virus in 
explanted vaginal mucosa [266].  In small intestine, however, macrophages lack surface 
receptors CD4, CCR5, and CXCR4 for viral entry and are not permissive to infection [266-268], 
consistent with our data.  Our finding that gut macrophages from animals with controlled SIV 
infection have largely intact phagocytic function is consistent with normal T cell and myeloid 
dendritic cell responses in intestine from natural SIV hosts [20, 223].  Moreover, animals with 
controlled SIV infection in our study had minimal intestinal damage and microbial translocation, 
comparable to findings in nonpathogenic SIV models that have less systemic immune activation 
and tissue-associated inflammation despite high levels of virus replication in blood and gut [21, 
85].  Together, these results suggest that altered macrophage phagocytic activity in SIV-infected 
small intestine is likely a consequence of the state of the local microenvironment and not direct 
viral infection.   
Our results allude to a compartmentalized cytokine response by accumulating CD163+ 
macrophages in gut compared to gut-draining mesenteric LNs, although in neither site did 
spontaneous macrophage cytokine activity appear to differentiate controllers and progressors.  In 
health, intestinal macrophages downregulate TLR-adaptor proteins MyD88 and TRIF as well as 
other innate signaling molecules in response to stromal-derived TGF-β and IL-10 to avoid 
adverse reactions towards enteric microbiota [115, 269, 270].  Previous studies have shown that 
TGF-β and IL-10 expression levels are elevated in HIV/SIV-infected gut mucosa, and therefore 
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these cytokines could potentially continue to act on newly recruited macrophages to promote a 
non-inflammatory phenotype [271-273].  Conversely, macrophages in mesenteric LNs from SIV 
progressors became increasingly responsive to stimulation by virus-encoded ligands, suggesting 
an enhanced ability to respond to mounting antigenic challenges as infection advances.  It is not 
clear whether other subsets of macrophages might accumulate in SIV-infected mucosal tissues 
and contribute a harmful response.  In HIV infection, CD14+ macrophage numbers are increased 
in colon from AIDS patients and express TNF-α and IL-1β, but whether these cells also express 
CD163 was not addressed [196].  Alternatively, it is possible that gut macrophages in animals 
with a progressive disease course switch to have an inflammatory function with the onset of 
AIDS [150]. 
Preservation of intestinal integrity is a key homeostatic function of gut macrophages 
[144, 247].  Functionally, CD163 can mediate such protection by sensing bacterial antigen and 
excessive hemoglobin deposits from lysed blood cells and promoting their uptake and 
degradation [274-276].  Our findings of increased non-inflammatory CD163-expressing 
macrophages in animals with increased intestinal breach suggest a role for macrophage 
recruitment and phagocytosis in mitigating tissue-associated inflammation and subsequent 
intestinal barrier breakdown [277].  Microbial translocation is a hallmark of HIV/SIV infection 
and a cause of chronic immune activation associated with progression to AIDS, and studies in 
HIV-infected humanized mice demonstrate a link between impaired macrophage phagocytic 
function, plasma LPS burden, and systemic T cell activation [91, 278].  Less appreciated are the 
effects of macrophage functional impairment on clearing excessive hemoglobin in tissues, which 
could have equally important pathologic consequences due to hemoglobin’s ability to induce 
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leukocyte production of TNF-α, IL-8, and IL-6 that may further trigger enterocyte apoptosis 
[140, 141].   
Our results suggest that CD163+ macrophage accumulation in intestine is derived from 
extravasated monocytes co-expressing CD163 and gut-homing marker α4β7.  Plasmacytoid 
dendritic cells in blood similarly upregulate α4β7 during SIV infection and accumulate in rectal 
tissues [88, 222].  Others have reported that differentiation of sorted monocytes into M2 
macrophages induces intra- and extra-cellular expression of CD163, and that the frequency of 
CD163+CD16+ monocytes is positively correlated with viremia in HIV infection [160, 259].  
Interestingly, at week 2 post-infection, all three monocyte subsets displayed evidence of 
increased gut homing, however only CD16+ monocytes had elevated CD163 levels that reflected 
differences in macrophage abundance in the chronic stage.  Previous studies have revealed that 
CD16+CD14- monocytes are preferentially expanded in acute and chronic SIV infection and 
share functional characteristics with intestinal CD163+ macrophages in our study [161, 279].  
Collectively, these data suggest that the CD16+CD14- monocyte subset and not CD14-
expressing monocytes likely represent the predominant source of gut macrophages during SIV 
infection.  Likewise, in Crohn’s disease patients, classical CD14+ monocytes selectively migrate 
to inflamed colon and phenotypically and functionally resemble newly accumulated CD14-high 
inflammatory macrophages [249].  A recent study found that blockade of α4β7-mediated homing 
in combination with ART treatment promoted virological control better than ART alone [280]; 
our results indicate it is likely this therapeutic approach might also have considerable impact on 
macrophage recruitment to gut mucosal tissues.   
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4.6 MATERIALS AND METHODS 
4.6.1 Animals and tissue preparation 
Indian-origin rhesus macaques housed at the University of Pittsburgh (U.S. Public Health 
Service Assurance Number:  A3187-01) were used in this study and all animal manipulations 
and procedures were done with appropriate institutional regulatory oversight and approval.  
Twelve macaques were selected with and 12 without expression of Mamu-B*008, a macaque 
MHC class I allele correlated with control of chronic phase plasma viral burden [26].  Macaques 
were inoculated intrarectally with 105 TCID50/mL of SIVmac251 and plasma was extracted from 
whole blood drawn periodically to monitor viral burden and for analysis of cells in circulation.  
Viral RNA in plasma was determined by RT-PCR as previously described [83].  Mesenteric LNs 
and resections of small intestine averaging 25cm in length were taken from each animal at two of 
the following timepoints:  pre-infection, or at weeks 2, 12, or 20 post-infection.  For isolation of 
mononuclear cells from intestine, tissues were minced and incubated in 5mM EDTA HBSS.  
Intestinal slurries were subsequently digested in 15 U/mL collagenase media, mechanically 
disrupted, and run on a Percoll gradient for leukocyte separation.  Suspensions of freshly isolated 
mesenteric LNs were generated as previously described [150].  Viral RNA in mesenteric LNs 
and intestinal suspensions was determined using RT-PCR and quantified per 1x106 cells.  Prior 
to processing, a portion of resected intestine was fixed in 2% paraformaldehyde and infused with 
30% sucrose for in situ analysis.  Tissues for IHC were frozen with an aerosol of 
chlorodifluoromethane and stored at -80°C. 
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4.6.2 Immunofluorescence microscopy and quantitative analysis  
Six-micron sections were cut from frozen intestine blocks and mounted on Superfrost Plus slides.  
Sections were briefly treated with 1% sodium dodecyl sulfate for epitope retrieval, washed 
thoroughly, and blocked in 5% of the secondary antibody host’s normal serum (goat, mouse, 
and/or donkey).  The following primary antibodies were then diluted in 0.5% serum and applied 
to slides at 4°C:  monoclonal mouse anti-human Cytokeratin (Clone MNF116, Dako), rabbit 
polyclonal anti-E.coli (Dako), monoclonal rabbit anti-hemoglobin (EPR3608, abcam), and 
monoclonal mouse anti-human CD163 Biotin (GHI/61, eBioscience).  Primary antibodies raised 
in rabbit were detected by donkey-anti-rabbit IgG Alex Fluor 546 secondary (Thermo Scientific) 
and antibodies raised in mouse detected using either goat anti-mouse Alex Fluor 546 or HRP-
Streptavidin Alexa Fluor 488 Tyramide Signal Amplification kits (Thermo Scientific) according 
to the manufacturer’s instructions.  Lastly, cell nuclei were identified using membrane permeable 
Hoescht dye and tissues mounted in gelvatol media for viewing on an Olympus Fluoview 1000 
confocal microscope.  All staining included an appropriately concentrated isotype-matched 
control antibody.  Quantification of in situ staining was carried out as previously described [102, 
150].  Briefly, macrophages were enumerated manually using ImageJ software (U.S. National 
Institutes of Health) and the total number of nuclei per image determined digitally using 
MetaMorph software (Molecular Devices).  Cell frequencies were calculated using the formula:  
(total number of macrophages x 5000) / total number of nuclei.  To determine extent of intestinal 
breach, the length of the epithelial interface between the lumen and lamina propria with and 
without cytokeratin expression was manually determined using the length measurement tool in 
NIS-Elements software (Nikon).  Percent breach was then ascertained using the formula:  
((length of no cytokeratin expression) / (length of no cytokeratin expression + length of 
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cytokeratin expression)) x 100.  Percent area of E.coli was determined manually by tracing using 
the NIS-Elements polygonal ROI function.  Percent E.coli+ area was calculated using the 
formula:  (area of lamina propria occupied by E.coli staining / total area of lamina propria) x 
100.  All data represent averages of quantification from ten nonoverlapping regions of lamina 
propria.   
4.6.3 Flow cytometry and phagocytosis assay  
Small intestine, mesenteric LNs, and PBMC cell suspensions were stained with the following 
cell surface-labeling anti-human antibodies (all antibodies were purchased from BD Biosciences 
unless otherwise noted):  HLA-DR (clone L243), CD163 (GHI/61), CD3 (SP34-2), CD4 (L200), 
CD20 (2H7, eBioscience), CD45 (D058-1283), CD14 (M5E2), CD16 (3G8), CD8 (RPA-T8), 
p27 (55-2F12, NIH AIDS Reagents), and α4β7 (A4B7, NHP Reagent Resource).  Nonviable 
cells were excluded with a fluorescent LIVE/DEAD cell stain (Invitrogen).  To measure 
responses to stimulation, freshly isolated intestinal and mesenteric LN single cell suspensions 
were cultured for 5 h with H7N3 influenza virus (MOI of 5), Env976 oligonucleotides 
(10µg/mL), or AT-2 iSIVmac239 (200ng capsid/mL) with or without brefeldin A (Sigma) 
treatment after 2 h before cell surface labeling.  Cells were then fixed and permeabilized using 
Cytofix/Cytoperm reagent (BD Biosciences) and subsequently stained with anti-human 
antibodies to TNF-α (Mab11), IL-6 (MQ2-6A3), and IFN-α (225.C, Chromaprobe).  Phagocytic 
activity was determined using the pHrodo Escherichia coli BioParticles Conjugate for 
Phagocytosis kit (Invitrogen) according to the manufacturer’s instructions with minor 
modifications.  Briefly, a suspension of 2x106 intestinal cells were incubated at 4°C or 37°C for 
1 h in a fixed volume of media before the addition of 50µL pHrodo for an additional 1 h.  Cells 
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were subsequently washed and stained with surface markers for macrophage identification.  All 
data were acquired using an LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo 
7.6.4 (TreeStar). 
4.6.4 Statistical analysis   
Cross-sectional comparisons between SIV progressors and controllers were performed using a 
regular two-way ANOVA followed by Sidak’s post test.  Longitudinal comparisons across 
multiple timepoints were performed using a nonparametric one-way ANOVA followed by 
Dunn’s post test.  Comparisons between two timepoints (e.g., pre-infection vs. week 20) were 
performed using a two-tailed nonparametric Mann-Whitney U test.  Correlations were 
determined using a two-tailed nonparametric Spearman rank test.  All aforementioned statistical 
tests were carried out using GraphPad Prism version 6.  Pie charts were analyzed using a 
permutation test performed with SPICE (version 5.22).  A p-value < 0.05 was considered 
significant.   
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5.0  CHAPTER THREE:  LYMPH NODE MACROPHAGES ARE ACTIVATED AND 
INFLAMMATORY IN SIV-INFECTED RHESUS MACAQUES REGARDLESS OF 
DISEASE COURSE 
5.1 PREFACE 
This chapter is in fulfillment of specific aim 3 and data herein will be incorporated into a 
separate manuscript for future publication. 
5.2 INTRODUCTION AND RESULTS 
Macrophages are specialized phagocytic cells of the innate immune system that participate in 
host inflammatory and antiviral responses in tissues throughout the body.  In lymph nodes (LNs), 
macrophages are situated within the subcapsular sinus and medullary regions where they uptake 
lymph-borne antigens and modulate adaptive immunity through antigen-presentation and 
cytokine production [117].  During pathogenic HIV and SIV infections, virus accumulates in 
lymphoid tissue, promoting progressive CD4+ T cell loss and profound anatomical damage 
associated with an unregulated inflammatory response [78, 281].  Cross-sectional studies 
demonstrate that macrophages infiltrate T-cell rich zones of secondary lymphoid tissue with 
acute SIV infection and AIDS suggesting a role for macrophages in disease pathogenesis [150, 
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190].  To date, no studies have prospectively analyzed the macrophage response in LNs to SIV 
infection and whether that response differs in animals predicted to control or progress to disease.  
Here, we utilized differential expression of SIV protective allele Mamu-B*008 (described in 
extensive detail in Chapter 2) to study macrophage kinetics and response in LNs from macaques 
with diverging disease courses [26].  Specifically, we evaluated macrophages prior to infection 
and at weeks 2, 12, and 20 post infection in axillary LNs, which drain lymph vessels from 
peripheral sites, and mesenteric LNs, which drain the mucosa.    
5.2.1 Acute SIV infection is associated with an accumulation of macrophages in LNs 
To monitor changes in macrophages following SIV infection, we generated single-cell 
suspensions of LNs using the same animals described in Chapter 2 (Table 2) and identified 
macrophages by flow cytometry gating on CD3/CD20-MHC-II+CD163+ cells (Fig. 9A).  
CD163+ macrophage frequency was dramatically increased in axillary LNs by week 2 or acute 
SIV infection compared to baseline percentages prior to inoculation (Fig. 9B).  By week 12, 
macrophage frequency had declined considerably, yet remained slightly elevated above pre-
infection levels at week 20.  Changes in macrophage frequency with infection were not 
associated with differences in cell turnover based on intracellular staining for proliferation 
marker Ki67 (Fig. 9B).  Moreover, cross-sectional analyses revealed no statistical differences in 
the percentage of macrophages in axillary LNs between SIV controllers and progressors.  Similar 
observations were made in gut-draining mesenteric LNs, with macrophage frequency markedly 
increasing in concert with peak viremia at week 2 and then declining at the onset of chronic 
infection regardless of disease course (Fig. 9C).  There was a minor but statistically significant 
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difference in Ki67+ macrophages between controllers and progressors at week 12, however in 
general there was no measurable change in cell turnover with infection (Fig. 9C).   
 
Figure 9.  Macrophages accumulate in LNs during acute SIV infection. 
(A) Representative flow cytometric analysis of peripheral LN single-cell suspensions showing gating strategy to 
define CD163+ macrophages.  (B) The proportion of CD163+ macrophages in the live cell fraction (Left) and the 
proportion of macrophages expressing Ki67 (Right) in axillary LNs (B) and mesenteric LNs (C) prior to infection 
and at weeks 2, 12, and 20 post-infection.  Red depicts macaques with set-point virus load >104 RNA copies/mL 
plasma (SIV progressors), and blue depicts macaques with set-point virus load <104 RNA copies/mL plasma (SIV 
controllers).  Horizontal lines in (C) represent medians.  # signifies cross-sectional differences between progressors 
and controllers and * signifies longitudinal differences within the same groups.  Statistical comparisons were done 
using a regular two-way ANOVA followed by Sidak’s post test (#) or nonparametric one-way ANOVA followed by 
Dunn’s post test (*).  Black asterisks reflect all animals.  */# p < 0.05; **/## p < 0.01; ***/### p < 0.001. 
 
5.2.2 LN macrophages are differentially activated and apoptotic in acute SIV infection 
We next evaluated whether differences in disease course were reflected in macrophage activation 
and cell death in SIV-infected macaques.  We stained for co-stimulatory molecules CD40 and 
CD86, as well as PDL1, a molecule that inhibits T cell activity, to assess macrophage activation 
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(Fig. 10A).  For analysis of cell death, we measured expression of Fas receptor CD95, also an 
indicator of cell activation, and intracellular active caspase-3 and caspase-1, which 
independently control induction of two mutually exclusive death pathways, apoptosis and 
pyroptosis, respectively [282].  Axillary LNs taken at week 2 displayed a uniform increase in 
CD86+ and CD95+ macrophages compared to pre-infection, reflecting heightened cellular 
activation, however infection had no impact on CD40 or PDL1 expression, and there were no 
statistical differences between groups (Fig. 10B).  Caspase-3 expression was also increased in 
macrophages during acute infection and there was a trend towards an increased frequency of 
caspase-1+ macrophages.  By week 12, macrophage activation and apoptotic status had returned 
to pre-infection levels and remained low out to week 20.  In contrast, in mesenteric LNs, 
macrophage activation status was significantly altered between groups but notably occurred 
before plasma viral load divergence.  Animals that went on to progress but not control SIV 
infection had a significantly higher proportion of macrophages expressing CD40 and CD86 
during acute infection, as well as higher active caspase-3 and caspase-1 expression (Fig. 10C).  
By week 12, macrophage activation and death in mesenteric LNs had reverted to pre-infection 
levels, similar to in peripheral LNs, reflecting the transient nature of these responses during 
infection.   
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Figure 10.  Differential activation and apoptosis of LN macrophages during acute SIV infection. 
(A) Representative flow cytometric analysis of axillary LN single-cell suspensions showing CD163+ macrophages 
expressing CD40, CD86, PDL1, CD95, active caspase-1, or active caspase-3 pre- and post-SIV infection.  (B and C) 
The proportion of macrophages expressing CD40, CD86, PDL1, CD95, active caspase-1, or active caspase-3 in 
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axillary LNs (B) and mesenteric LNs (C) prior to infection and at weeks 2, 12, and 20 post-infection.  Red depicts 
SIV progressors and blue depicts SIV controllers.  Horizontal lines in (C) represent medians.  # signifies cross-
sectional differences between progressors and controllers and * signifies longitudinal differences within the same 
groups.  Statistical comparisons were done using a regular two-way ANOVA followed by Sidak’s post test (#) or 
nonparametric one-way ANOVA followed by Dunn’s post test (*).  Black asterisks reflect all animals.  */# p < 0.05; 
**/## p < 0.01; ***/### p < 0.001.  
 
5.2.3 Gut macrophages in SIV infection are not activated or apoptotic 
In our previous study, gut macrophage abundance after viral set-point was strongly correlated 
with plasma viral load, in contrast to macrophage numbers in LNs.  We next determined whether 
macrophages that accumulate in gut mucosa in progressive SIV infection are differentially 
activated and apoptotic compared to macrophages in SIV controllers as well as assessed how 
changes in gut macrophage kinetics relates to changes in LN macrophages.  As carried-out in 
LNs, gut macrophages were identified as CD163-positive by flow cytometry and evaluated for 
expression of Ki67, CD86, CD95, and active caspases-3 and -1 before and after infection (Fig. 
11A).  In contrast to axillary and mesenteric LNs, however, there was no alteration in the 
frequency of gut macrophages expressing CD86 or caspases-3 and -1 and no indication of 
increased macrophage turnover with SIV infection (Fig. 11B).  Acute SIV infection was 
associated with a temporary increase in the percentage of CD95+ macrophages, but this subsided 
by week 12.   
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Figure 11.  SIV infection has no impact on macrophage activation or apoptosis in gut mucosa. 
(A) Representative flow cytometric analysis of small intestine single-cell suspensions showing CD163+ 
macrophages expressing Ki67, CD86, PDL1, CD95, active caspase-1, or active caspase-3 pre- or post-SIV infection.  
(B) The proportion of macrophages expressing Ki67, CD86, PDL1, CD95, active caspase-1, or active caspase-3 in 
small intestine.  Red depicts SIV progressors and blue depicts SIV controllers.  Horizontal lines in (B) represent 
medians.  # signifies cross-sectional differences between progressors and controllers and * signified longitudinal 
differences within the same groups.  Statistical comparisons were done using a regular two-way ANOVA followed 
by Sidak’s post test (#) or nonparametric one-way ANOVA followed by Dunn’s post test (*).  Black asterisks reflect 
all animals.  */# p < 0.05; **/## p < 0.01; ***/### p < 0.001. 
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5.2.4 Increased proinflammatory response by macrophages in axillary LNs during SIV 
infection 
To determine if controlled and progressive SIV infection is associated with differential 
inflammatory activity by LN macrophages, we next measured macrophage cytokine response ex 
vivo to viral agonists iSIV, influenza, and Env976 (Fig. 12A).  Few LN macrophages from 
uninfected animals secreted combinations of TNF-α, IL-6, and IFN-α spontaneously but readily 
produced cytokines following stimulation with Env976 and iSIV (Fig. 12B).  After SIV 
infection, there was a marked increase in the frequency of cytokine+ macrophages in axillary 
LNs, predominantly expressing TNF-α and IL-6, that remained elevated over pre-infection levels 
out to week 12.  Furthermore, this contrasted with findings in mucosal tissues, where there was 
little change in cytokine production by gut macrophages with SIV infection and only trends in 
mesenteric LNs (see Fig. 8, Chapter 2).  The percentage of cytokine+ macrophages in axillary 
LNs also increased after agonist exposure with SIV infection; however, the levels were 
comparable to cytokines produced spontaneously (Fig. 12B).  Unexpectedly, SIV controllers had 
just as robust a cytokine response as animals anticipated to progress to disease.  Only in LNs 
stimulated with Env976 did we detect differences between groups, with macrophages from SIV 
progressors producing significantly more cytokines than SIV controllers at week 20.  Together, 
these data are consistent with an inflammatory function for accumulating LN macrophages in 
SIV infection, however there was no relationship with controlled or progressive disease 
outcomes. 
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Figure 12.  Macrophages in axillary LNs produce proinflammatory cytokines during SIV infection. 
(A) Representative flow cytometric analysis of axillary LN single-cell suspensions showing CD163+ macrophage 
production of TNF-α, IL-6, and IFN-α after Env976 stimulation compared to an IgG control.  (B) SPICE analysis of 
the proportion of axillary LN CD163+ macrophages in culture producing different permutations of TNF-α, IL-6, and 
IFN-α prior to infection and at weeks 2, 12, and 20 post-infection either spontaneously or after stimulation by 
Env976, Influenza, or iSIV.  Statistical comparisons were done using a permutation test performed with SPICE 
software.  # signifies cross-sectional differences between progressors and controllers and * signifies longitudinal 
differences within the same groups.  Red asterisks reflect SIV progressors and blue asterisks reflect SIV controllers.  
*/# p < 0.05; **/## p < 0.01; ***/### p < 0.001. 
 
5.3 DISCUSSION 
In this study, we investigated the impact of controlled and progressive SIV infection on 
macrophage kinetics and function in secondary lymphoid tissues.  Our results expand on 
previous reports of increased macrophage numbers in acutely SIV-infected LNs and demonstrate 
accumulation occurs regardless of whether macaques go on to control chronic phase viremia 
 77 
[101, 190].  We also reveal LN macrophages are activated and produce inflammatory TNF-α and 
IL-6 in SIV infection, supporting the supposition that macrophage recruitment to tissues is 
harmful and may contribute to disease pathogenesis.  Our data however provide nuance to this 
notion, as we uncover negligible differences in the macrophage inflammatory response between 
animals anticipated to control or progress to disease.  Instead, we propose that while 
macrophages may contribute to early tissue inflammation, immune activation, and T cell loss in 
LNs, they do not appear to define a progressive disease outcome.  
In addition to responding to TLR ligands ex vivo after SIV infection, LN macrophages 
also produced cytokines spontaneously.  This suggests macrophages may be stimulated by the 
presence of virus in tissues, similar to myeloid DCs in HIV patients [283].  The likeness in 
macrophage responses between SIV controllers and progressors points towards comparable 
levels of viral antigen in LNs, at least until week 20.  Indeed, prospective studies on viral kinetics 
in SIV-infected macaques have shown that virus replication is stable in LNs out to day 100 and 
not reflective of changes in plasma viral load [264].  Cytokines produced by macrophages in 
chronic infection, however, are likely elicited from the combined exposure to viral and microbial 
antigens, as E.coli products are not detectable in peripheral LNs during the acute stage [90].  
Notably, Env976-activated macrophages became increasingly responsive after viral set-point in 
SIV progressors, achieving statistical significance compared to macrophages from controllers in 
the chronic stage.  Although we did not examine macrophages beyond week 20, these data allude 
to a potential pathologic role for macrophages in advanced infection that may participate in 
ongoing T cell activation and associate with AIDS.    
The factors driving changes in macrophage dynamics that distinguish the acute and 
chronic stages of SIV infection are currently unknown.  Antiretroviral treatment at day 7 post-
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SIV infection inhibits macrophage influx to LNs and is associated with reduced BrdU 
incorporation by monocytes, suggesting accumulation may be mediated by initial virus 
expansion and/or virus-induced inflammation [101].  Furthermore, therapy partially reverses 
expression of several chemotactic factors, including CCL5, which are otherwise upregulated in 
ART-naïve HIV-infected LNs and promote monocyte extravasation from blood [281, 284, 285].  
HIV and SIV infections are associated with an expansion of CCR5-high CD16+ monocytes, 
indicating macrophage recruitment in the acute stage might be derived from monocyte 
trafficking via a CCR5-CCL5 dependent pathway [161, 182, 184].  Interestingly, the percentage 
of macrophages in LNs declined considerably by week 12, regardless of viral set-point.  Our data 
point towards caspase-3 and capase-1 dependent cell death playing a role in the macrophage 
decline, possibly a function of direct viral infection and/or interactions between tissue-associated 
TNF-α and death-receptor CD95, a mechanism of T cell loss in HIV/SIV infection [286-288].   
In our study, infection with SIV had no impact on the proportion of Ki67+ macrophages 
in LNs or small intestine.  Circulating monocytes therefore likely represent the initial and 
predominant source of macrophages in LNs during the early stages of infection.  Conversely, 
others have shown that LN macrophages undergo a pronounced regenerative response in 
advanced chronic infection, defined as well beyond week 20 post-infection, and in AIDS, and is 
consistent with findings of increased perivascular macrophage proliferation in HIV-infected 
brain [150, 195, 289].  It is possible macrophage self-renewal may be to counteract increasing 
monocyte dysregulation due to monocytes becoming progressively more apoptotic with infection 
and being persistently recruited across multiple tissues, including lung and gut mucosa [244, 284, 
290, 291].   
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Collectively, our data reveals significant anatomical differences in macrophage activation 
during SIV infection and is in agreement with a cross-sectional comparison of macrophages 
across multiple tissues [153].  Our data suggest that evidence of macrophage functional and 
phenotypic heterogeneity in health, governed largely by cytokines derived in the environment, is 
likewise manifested across a spectrum of responses in disease, including HIV/SIV infection 
[292-294].  Under homeostatic and inflammatory conditions, tissues serve unique functional 
roles that also shape macrophage diversity, such as immuno-priming and augmentation in LNs 
versus immunoregulation in gut mucosa.  Accordingly, we observed enhanced co-stimulatory 
molecule expression by macrophages in both axillary and mesenteric LNs but minimal activation 
of macrophages in gut mucosa in response to SIV infection.  Further comprehensive assessments 
of macrophages across multiple tissues and different stages of infection will be important to 
elucidating the contributions of macrophages to disease control and progression.   
5.4 MATERIALS AND METHODS 
Information regarding animals, virus infection, tissue sampling and processing, macrophage 
identification by flow cytometry, and ex vivo cell stimulations with virus carried-out in this 
chapter are reported in Chapter 2.  Information regarding analysis of macrophage activation and 
death by flow cytometry is reported below: 
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5.4.1 Flow cytometry 
Single-cell suspensions of LNs and small intestine were stained with the following cross-reactive 
surface-labeling anti-human antibodies for analysis of CD163+ macrophage activation, turnover, 
and death (all antibodies were purchased from BD Biosciences unless otherwise noted):  CD86 
(clone FUN-1), CD40 (5C3), PDL1 (29E.2A3, BioLegend), and CD95 (DX2).  Nonviable cells 
were excluded by staining with a fluorescent LIVE/DEAD cell stain (Invitrogen).  Detection of 
active caspase-1 was conducted using the FAM-FLICA Caspase-1 Assay Kit (ImmunoChemistry 
Technologies) per the manufacturer’s instructions with minor modifications.  Briefly, 5µl of 30x 
FLICA probe was added to 2.5x106 cells in 300µL of MACS buffer, incubated at 37°C for 1 h, 
and then washed thoroughly before surface stain.  Intracellular analysis of nuclear protein Ki67 
(B56) and active caspase-3 (C92-605) were conducted after permeabilization with 
Cytofix/Cytoperm (BD Biosciences).  Cells were exposed to 610µW/cm2 UV-B light for 5 mins 
as a positive control for apoptosis and pyroptosis.  Data were acquired using an LSRII flow 
cytometer (BD Biosciences) and analyzed using FlowJo 7.6.4. 
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6.0  OVERALL DISCUSSION 
6.1 CD163 AS A MARKER OF MACROPHAGES IN SIV INFECTION 
The phenotypic characterization of cells based on surface antigen expression is complicated with 
respect to macrophages given their remarkable heterogeneity and plasticity across tissues.  
CD11b, CD68, CD14, calprotectin (MAC387), and CD206 have all been used to some extent to 
identify macrophages in different organs and in different models; however, antibodies to each of 
these molecules also overlap in specificity with fibroblasts, endothelial cells, and other 
leukocytes [295-298].  Alternatively, the markers HAM56, CD169 (Siglec-1), and CD163 are 
putatively restricted to cells of the monocyte/macrophage lineage, however these markers 
notably do not encompass all macrophages, and furthermore, macrophages they are expressed on 
may behave differently depending on the tissue they occupy [298-304].   
For this study, we elected to use CD163 to define a subset of macrophages based on a 
growing body of evidence of the involvement of CD163-positive cells in HIV/SIV infection but 
an absence of information on their contribution to disease pathogenesis [89, 148, 151, 160, 190, 
191, 193, 194, 208, 259, 289, 305-308].  CD163 is a transmembrane glycoprotein and high 
affinity scavenger receptor for complexes of hemoglobin and haptoglobin in plasma and in 
tissues [139, 309].  Removal of free hemoglobin is a principal function of macrophages due to its 
inflammatory and oxidative properties, and CD163’s unique ability to mitigate hemoglobin-
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induced damage originally contributed to its distinction of recognizing an “anti-inflammatory” 
macrophage [309, 310].  CD163 has since been reported to also function as an innate sensor for 
the recognition of some bacteria and viruses and binds and sequesters TNF-α superfamily 
molecule TWEAK, preventing TWEAK-associated pathologic changes, such as apoptosis [311-
313].  Macrophages expressing CD163 have been linked to a myriad of M2-like functions, 
including the promotion of Th2 polarized responses and the secretion of arginase-1 as well as 
various angiogenic and tissue growth factors [136, 314].  However, expression of CD163 is not 
restricted to M2 macrophages, as demonstrated in tissues from patients with chronic venous leg 
ulcers, where CD163+ cells populate wounds and express TNF-α, iNOS, and IL-12 [315].  In 
health, certain tissue resident macrophages constitutively express high levels of CD163, 
including those located in the gastrointestinal tract, bone marrow, liver, and lung [310].  In 
addition to HIV/SIV infection, increases in CD163+ macrophages and/or macrophage shed 
sCD163 are associated with acute hepatitis, malaria, and tuberculosis infections, as well as in 
chronic non-infectious illnesses including Crohn’s disease, rheumatoid arthritis, coeliac disease, 
and scleroderma [316-321].   
While the use of CD163 does not likely reflect the activity or responses of all 
macrophages in the SIV-infected macaques used in our study, it does allow for the analysis of a 
discrete population of macrophages, based on a common identifier, that are unmistakably a 
feature of various inflammatory settings.  Others have reported that CD14+CD68+ macrophages 
accumulate and promote inflammation in colon from AIDS patients, and that CD169+ 
macrophages capture HIV and trans-infect CD4+ T cells in spleen and lymph nodes [170, 196].  
Whether these cells also express CD163 or represent entirely unique subsets of macrophages 
acting in parallel is not clear and should be the focus of the future hypotheses.    
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6.2 DIFFERENTIAL RESPONSES BY MACROPHAGES EXPRESSING CD163 IN 
LYMPH NODES AND GUT MUCOSA  
In our model of SIV infection, CD163 defined a population of macrophages that were activated 
and pro-inflammatory in lymph nodes but not activated and non-inflammatory in small intestine.  
Furthermore, we found that there was differential recruitment of macrophages between lymph 
nodes and gut mucosa depending on the stage of infection and disease outcome.  These data 
indicate a compartmentalized response to SIV infection that warrants continued investigation if 
we are to effectively intervene and alter macrophage activity for the wellbeing of HIV-infected 
patients.    
In the small intestine, we found that quantitative changes in macrophage numbers 
mirrored plasma viral load kinetics in acute and chronic SIV infection, suggesting a role for viral 
burden in mediating divergence in macrophage recruitment.  Interestingly, CD163+ and CD68+ 
macrophages also accumulate in mucosa from SIV-naive macaques with experimentally-induced 
colitis and in lamina propria of colon and ileum from individuals with Crohn’s disease, 
ulcerative colitis, and spondyloarthritis [265, 322, 323].  Moreover, while viral RNA in plasma 
was statistically significant between groups in our study, the level of cell-associated virus in 
intestine from the same animals was comparable.  These data instead point towards a relationship 
between CD163+ macrophage recruitment and pathologic changes in gut, such as microbial 
translocation and/or endogenous cues pertaining to tissue inflammation and injury, and not to the 
presence of virus [91].  Consistent with this hypothesis, in a pathogenic model of SIV, macaques 
administered a TNF-α inhibitor subcutaneously had reduced CD163+ macrophage numbers in 
peripheral lymph nodes but no change in plasma viremia compared to untreated control animals 
[190].  It is also possible that the persistent recruitment of macrophages in SIV progressors 
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reflects a compensatory response by the host to overcome gut macrophage phagocytic defects.  
Similar observations have been made of CD4+ T cells, where the continued proliferation of 
memory CD4+ T cells in blood and subsequent relocation to tissues counteracts SIV-associated 
CD4+ T cell loss and differentiate macaques with stable infection from those that progress 
rapidly to disease [324].  In conflict with our findings, a separate study found a strong positive 
correlation between chronic phase plasma viral load and SIVmac251 replication in macaque 
ileum and rectum but not spleen, peripheral lymph nodes, or mesenteric lymph nodes [264].  
Given that the controller sample size was 3 animals and there was a convincing trend towards a 
similar relationship in our study, it is possible that with the addition of more data points the SIV 
controller group would have significantly less cell-associated virus in intestine than SIV 
progressors at week 20.         
Although we found changes in gut macrophage numbers that distinguished controllers 
from progressors, CD163+ macrophages were not activated or responsive to viral stimuli in 
either group.  In an uninfected healthy gut, the constitutive expression of cytokines TGF-β and 
IL-10 play an obligate role in preventing LPS-induced intestinal damage through their 
interactions with local cell populations [115, 269].  As illustrated in murine models with gut 
macrophages engineered to be nonresponsive to IL-10 or TGF-β and with macrophages isolated 
from human intestine, these cytokines avert harmful M1-like responses by suppressing 
macrophage proinflammatory but not phagocytic or bactericidal activity [116, 270, 325, 326].  In 
chronic HIV and SIVmac infections, the frequency of TGF-β producing T regulatory cells is 
markedly increased in gut mucosa and corresponds with increased TGF-β tissue expression [271, 
272, 327].  Mucosal IL-10 levels are also increased in models of SIV infection, however one 
study reported no change, and in HIV-infected colonic tissues IL-10 is significantly reduced 
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following antiretroviral treatment [273, 328, 329].  Based on these data, our results may indicate 
that newly recruited macrophages are adequately tolerized upon arrival to gut, possibly due to 
robust mucosal IL-10 and TGF-β responses to SIV infection and in spite of other alterations in 
the intestinal cytokine milieu.  HIV-associated immuno-suppressive responses have been shown 
to have unintended consequences, however, such as dampening CD8+ T cell-mediated antiviral 
immunity, and is manifest in findings that TGF-β levels in intestinal lymphoid organs are 
positively correlated with rapid progression to AIDS [327].  One limitation of our study is that 
we did not assess gut macrophage cytokine responses to TLR4 ligands, such as bacterial LPS, 
after SIV infection.  Stimulation of intestinal macrophages from AIDS patients with LPS elicits 
increased macrophage TNF-α, IL-1β, IFN-γ, and IL-18 mRNA expression [196].  IRAK-M, a 
negative regulator of TLR4-mediated signaling, promotes tolerance towards microbial products 
in macrophages and is upregulated by macrophages in a human endotoxemia model [330, 331].  
To date, no studies have investigated IRAK-M expression in macrophages in the context of HIV 
and SIV, and it is possible IRAK-M plays a central role in influencing macrophage activity 
towards gut translocated microbes at different stages of infection.   
In contrast to gut mucosa, macrophages in lymph nodes were activated, apoptotic, and 
inflammatory, primarily in acute infection, however macrophage cytokine production persisted 
after viral set-point to an extent in both groups.  Increases in cell surface CD40 and CD86 
associated with macrophage emigration to lymph nodes suggest macrophage participation in 
antigen-presentation and T cell responses.  However, a recent study from our group found that 
the ability of lymph node macrophages in SIV infection to stimulate naïve allogeneic CD4+ T 
cell proliferation is significantly impaired due to defective IL-12 and IFN-α production and not 
co-stimulatory molecule expression [100].  In agreement with these data, lymph node 
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macrophages in our study were also poor producers of IFN-α, even after additional ex vivo 
activation.  Interestingly, alterations in TGF-β and IL-10 expression in HIV/SIV-infected lymph 
nodes are similar to those reported in intestinal tissues [332-334].  When compared within the 
same study, however, IL-10 levels in gut mucosa exceeded those in matched lymph nodes from 
patients with symptomatic acute HIV infection, and therefore might explain in part the 
differences in macrophage activation between the two compartments [335].  We found that 
lymph node macrophage frequency declined after viral set-point, following an acute increase in 
caspase-1 and caspase-3 expression, suggesting cell death.  Cell death is a well-defined 
mechanism of myeloid cell loss in HIV/SIV-infected lymph nodes, mediated by direct virus 
infection and/or bystander killing depending on the cell type, and is proposed to be the primary 
mode of macrophage clearance from inflamed tissues [83, 84, 336].  Paradoxically, macrophages 
are reported to be resistant to the cytopathic effects of virus, contributing to their longevity as a 
viral reservoir during infection, even after depletion of CD4+ T cells [173, 174, 337, 338].  It is 
possible our findings reflect a transient and beneficial reaction by the host to clear an over-
abundance of macrophages in acutely-infected lymph nodes and that the residual macrophage 
population is more resilient to death [336].   
6.3 MONOCYTES AS A SOURCE OF GUT MACROPHAGES  
Integrin α4β7 provides an important pathway for circulating CD4+ T cells and other blood 
leukocytes to home to mucosal tissues [339].  Recently, its expression on plasmacytoid DCs in 
the context of HIV/SIV infection was shown to associate with plasmacytoid DC accumulation in 
colorectum and intestine [88].  In our study, the induction of α4β7 on monocytes in response to 
 87 
SIV infection coincided with a prominent increase in intestinal CD163+ macrophages.  We 
further found that expression of CD163 on α4β7+ monocytes, specifically the CD16+CD14- 
subset, paralleled differences in macrophage numbers between groups.  Collectively, these 
observations suggest that accumulating CD163+ macrophages in SIV-infected intestine are 
derived from monocyte extravasation mediated by α4β7.   
The mechanisms by which infection influences the recruitment of CD16+ monocytes to 
gut mucosa in SIV infection are currently not clear [91].  Studies investigating the effects of 
tolerance in cancer patients show that intravenous administration of LPS alters the ratio of 
monocyte subsets in favor of CD16-positive monocytes, suggesting a role for microbial 
translocation [340].  In mice, CD16-equivalent monocytes with attenuated inflammatory activity 
are recruited to heart with myocardial ischemic injury and promote angiogenesis and collagen 
deposition, suggesting tissue damage may also be driving recruitment [341].  Interestingly, the 
balance of non-inflammatory CD16+CD14- monocytes, which dominant blood in acute and 
chronic SIV infection as reported by others, is skewed in favor of the inflammatory CD14-
expressing monocyte subsets in SIV/AIDS [161].  This would be consistent with the progression 
from a non-inflammatory CD163+ macrophage found in acute and chronically SIV-infected 
intestine to a TNF-α+ macrophage in gut with AIDS in our study.  Continued research into the 
signals that elicit the differential migration of specific monocyte subsets to SIV-infected mucosa 
could expose novel avenues for therapeutic manipulation of downstream macrophage responses. 
Our study does not address whether monocytes utilize other mechanisms in unison with 
the α4β7 pathway to traffic to intestine.  Altered CCR2/CCL2 and CD31/ICAM-1 expression 
also induce monocyte emigration to inflamed mucosal tissues, as demonstrated in inflammatory 
bowel disease (IBD) and tuberculosis models, and associate with quantitative increases in 
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macrophages [248, 342, 343].  In chronic HIV-infected duodenum, CCL2 protein levels are 
elevated in conjunction with intestinal macrophage numbers and blood monocyte CCR2 
expression [89].  Chemokine receptor CCR9 also plays a role in peripheral leukocyte trafficking 
to mucosa, responding to its ligand CCL25, however CCL25 is expressed poorly in terminal 
ileum, the segment of small intestine examined in our study [344, 345].  Interestingly, SIV 
infection results in the upregulation of the CCR5 ligand CCL5 in lymph nodes, lung, and 
intestine [346].  It is possible that CD16+ monocytes, which selectively express CCR5, are 
drawn to lymph node or gut contingent on the expression of α4β7 in HIV/SIV infection [159-
161].  The homing of α4β7+ cells to gut is governed by its interaction with MAdCAM-1 on gut 
endothelial venules [347].  While we did not investigate MAdCAM-1 in our study, its levels are 
markedly elevated in duodenum from AIDS patients with or without ART as well as in other 
mucosal inflammatory conditions [347, 348].  Lastly, our conclusion that macrophages are 
derived from α4β7-expressing monocytes is further supported by findings that in vivo treatment 
with an anti-α4 integrin antibody significantly reduces CD68+ macrophage burden in gut, which 
independent studies have shown also express CD163, in addition to heart and brain of SIV-
infected macaques, and has similar effects in mice and humans [162, 349-352].   
In addition to being an important pathway for peripheral cells to home to mucosal tissues, 
α4β7 can also serve as a receptor for HIV binding and facilitate dissemination of HIV/SIV to 
gut-associated target cells [353, 354].  Recent studies in SIV-infected macaques reveal that ART 
treatment in combination with an anti-α4β7 antibody suppresses viral replication in plasma and 
gastrointestinal tissues to undetectable levels compared to ART alone, even after discontinuation 
of α4β7 antibody therapy [280].  Moreover, the authors report the restoration of intestinal CD4+ 
T cell populations, including Th17 and Th22 cells, important for intestinal barrier health, 
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however they do not comment on the integrity of the intestine following therapy discontinuation 
[92, 95, 165].  These findings could have implications for α4β7-driven macrophage recruitment 
to gut in SIV progressors.  Our data suggest that a reversal of gut epithelial damage in pathogenic 
SIV infection, potentially a function of reconstituted Th17 and Th22 cell subsets, could associate 
with diminished monocyte/macrophage recruitment to intestine and restored phagocytic function. 
6.4 ROLE OF MACROPHAGE INFLAMMATORY ACTIVITY IN CONTROLLED 
AND PROGRESSIVE SIV INFECTION 
Macrophages produce low levels of inflammatory mediators in health and quantitative increases 
in their numbers and cytokine activity feature prominently in inflamed tissues.  Inflammation 
plays a vital role in accelerating host defense and pathological healing but can simultaneously 
exacerbate these processes if inadequately controlled [355].  Bacterial infections, for example, 
benefit from an early and robust inflammatory response by M1-like macrophages, producing 
nitric oxide, TNF-α, and IL-1β upon activation to stymie growth of Salmonella typhi, 
Mycobacterium tuberculosis, and Listeria monocytogenes, among others [127-129].  
Alternatively, excessive stimulation of macrophages in the context of bacterial infection can 
result in macrophage-mediated sepsis via cytokine storm [356].  Newly-emigrated macrophages 
are often a source of inflammation in disease, supplemented by monocytes responding to 
chemotactic cues either derived from the pathogen itself or in response to pathogen-induced 
inflammatory mediators [357].  Studies in murine models demonstrate that inhibition of 
monocyte recruitment, either through antibody-blockade or vector-mediated suppression, reduces 
macrophage burden in atherosclerotic lesions and regresses disease pathology [358, 359].   
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In HIV/SIV infection, monocytes and macrophages can be activated by certain pathogen-
associated antigens to produce inflammatory mediators within the environment.  LPS is an outer 
membrane component of gram-negative bacteria that is present in tissues and in circulation 
during infection, can activate macrophages through TLR4, and is strongly correlated with 
measures of immune activation and progression to disease [91].  Similarly, HIV-derived ssRNA 
nucleotides activate monocytes/macrophages through TLR8, and in vitro co-culture of 
monocytes with naïve CD8+ T cells in the presence of HIV oligonucleotides significantly 
increases CD8+ T cell activation, an effect not seen when monocytes are excluded [360].  
Nevertheless, to date, few studies have addressed the macrophage response in the context of 
stable infection, leaving the question of the extent of macrophage involvement in disease-
associated inflammation and AIDS pathogenesis ill-defined. 
In our study, we find an increased frequency of proinflammatory macrophages coincident 
with macrophage influx to lymph nodes in acute SIV infection compared to in health.  Even with 
the onset chronic infection, macrophages continued to produce TNF-α, IL-6, and IFN-α, however 
macrophage frequency had declined to pre-infection levels, reducing the relative magnitude of 
their contribution to overall lymph node inflammation.  A hallmark of acute HIV/SIV infection 
is the pronounced expression of proinflammatory genes and cytokines in lymphoid organs, 
including TNF-α, IL-6, and IFN-α, which our data suggest are partially macrophage in origin 
[361].  While these results point towards a pathologic function for lymph node macrophages in 
SIV infection, this effect was observed in both controllers and progressors, and therefore may 
instead reflect an orderly inflammatory response intended to amplify surrounding immune 
activity and mediate antiviral host defense.  The sustained spontaneous production of 
inflammatory mediators by macrophages above pre-infection levels in the chronic stage, 
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however, may offset any benefit of an initial protective effect and ultimately perpetuate 
inflammation-induced tissue damage and immunopathology.  Interestingly, when compared to 
macaques with controlled SIV infection, we found that Env976 stimulated macrophages in SIV 
progressors became increasingly responsive in the chronic stage.  These findings demonstrate 
that lymph node macrophages may eventually contribute to tissue inflammation through chronic 
virus stimulation of TLR8.  Conversely, lymph node macrophages were not responsive to 
influenza ex vivo, which activates innate cells through TLRs 3,7/8 and RIG-I, suggesting 
macrophages after SIV infection may be unable to contribute an innate response towards 
opportunistic pathogens.    
In contrast to macrophages in SIV-infected lymph nodes, newly recruited CD163+ 
macrophages in small intestine were functionally non-inflammatory.  Patients with IBD present 
with similar enteropathies as found in HIV infection and in SIV progressors from our study, such 
as intestinal breach, microbial translocation, and a pronouncement of macrophages in mucosal 
tissues, particularly around blood vessels suggesting monocyte origin [322, 362, 363].  In IBD, 
however, aberrant gut macrophage cytokine activity is a key proinflammatory pathway driving 
disease pathology, and our data would suggest the contrary for gut macrophages in acute and 
chronic SIV infection [364].  One limitation of our study is that use of CD163 may preclude the 
possibility of the recruitment of multiple macrophage subsets to gut mucosa during infection, 
some of which may participate in SIV-associated intestinal inflammation.  Indeed, CD163+ cells 
also become abundant in intestinal tissues from IBD patients, however whether they convey a 
pro- or anti-inflammatory function was not addressed [322, 323].  Instead, IBD-related 
inflammation appears to be amplified by an accumulation of CD14-high TREM-1+ 
macrophages, consistent with one finding in colon from AIDS patients, and which do not express 
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CD163 [196, 250, 263, 365, 366].  Another possibility could be that macrophage subsets are 
differentially recruited along the gastrointestinal tract in response to infection.  The 
aforementioned studies on inflammatory macrophages in AIDS or IBD focused on a region of 
the large intestine, which differs considerably in function, structure, and microbiota composition 
compared to small intestine [86, 367].  Consistent with this hypothesis, in health and in chronic 
SIV infection, colonic macrophages were found to differ phenotypically and functionally from 
macrophages in jejunum [153].   
In spite of this finding, in the context of AIDS, we found evidence that intestinal CD163+ 
macrophages express TNF-α and IFN-α, consistent with an inflammatory function.  Indeed 
macrophage function at one stage of disease is not always reflective of their function in a later 
stage, as demonstrated in a model of inflammatory lung disease, suggesting macrophages have 
the capacity to switch phenotypes as disease progresses [368].  Consistent with this notion, 
monocyte expansion in acute and chronic SIV infection favors the CD16+CD14- subset but in 
AIDS switches in favor of CD14-expressing monocytes [161].  Our data may suggest that the 
persistent accumulation of CD163+ macrophages associated with a progressive disease course 
gradually becomes pathologic as infection advances and thus participates in mucosal 
inflammation.  This response might be mediated in part by impaired monocyte maturation 
through decreased CD16 expression and/or a gradual buildup of antigenic debris which could 
chronically stimulate macrophages, perhaps a consequence of an impaired phagocytic response 
established earlier in infection.  It is also possible that variation in macrophage responses 
between infection and AIDS in gut mucosa could be a function of the presence of opportunistic 
infections associated with disease.  Although enterocyte loss was evident in SIV progressors 
during the early chronic stages of infection (week 12), macrophage-secreted TNF-α in AIDS 
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could perpetuate disruption of the epithelial repair process and prevent reformation of the 
intestinal barrier [132].   
A limitation of our study is that we did not investigate the production of anti-
inflammatory (TGF-β, IL-4, IL-10, IL-13, arginase-1) or other pro-inflammatory (IL-1β, IL-12, 
iNOS) cytokines by lymph node and gut macrophages.  CD163+ macrophage accumulation in 
SIV-infected lymph nodes and heart is associated with increased tissue fibrosis, which could be 
driven by macrophage-derived TGF-β [151, 190].  Moreover, it is possible that gut macrophage 
production of tissue growth factors, such as HGF, played a role in the differential maintenance of 
the intestinal barrier between controllers and progressors [144].  Future studies should aim to 
provide a more comprehensive and complete assessment of macrophage cytokine responses in 
the context of controlled and progressive disease outcomes to fully appreciate the role of 
macrophages in HIV/AIDS pathogenesis. 
6.5 CHANGES IN MONOCYTES/MACROPHAGES THAT PRECEDE DISEASE 
PROGRESSION 
In chronic HIV and SIV infections, the frequency of CD163+CD16+ monocytes in blood is 
proposed as a biomarker for AIDS progression given its strong correlation to plasma viral load 
[156, 160, 161, 369].  Based on similar correlations, other groups have reported increases in 
monocyte/macrophage activation as measured by plasma sCD163 levels to be an early indicator 
of disease prognosis and AIDS-associated dementia [191, 194, 195, 370].  While these data are 
seemingly contradictory given sCD163 is shed by monocytes/macrophages, studies have shown 
that sCD163 levels inversely correlate with surface CD163 on CD16-CD14+ monocytes and not 
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CD16+CD14- monocytes [371].  Notably, monocyte upregulation of CD163 may reflect 
maturation into tissue macrophages [259, 372].  Our data expand on this body of knowledge and 
demonstrate that macrophage activation in mesenteric lymph nodes and increased CD16+ 
monocyte CD163 expression are apparent prior to viral set-point in animals that eventually 
develop progressive infection.  Furthermore, we found that CD163 expression on CD16+ 
monocytes remained elevated after set-point and associated with viral burden, consistent with the 
previously mentioned studies.  These data indicate that early changes in monocytes/macrophages 
might influence or predict disease outcome and therefore could have prognostic value after HIV 
infection.  Although isolating mesenteric lymph nodes for evaluation of macrophages is not 
feasible, an assessment of monocytes in blood could conceivably be paired with other predictive 
measures of disease progression, such as T cell proliferation and viremia, to more reliably inform 
drug treatment commencement and efficacy [373].  In addition, with insight into the relationship 
of monocyte CD163 expression and tissue CD163+ macrophages in SIV infection, particularly in 
the small intestine, clinicians hoping to target macrophages for therapeutic purposes could 
potentially use monocytes as a window into gut-associated macrophage activity prior to and after 
treatment.   
6.6 MECHANISMS OF MACROPHAGE DYSFUNCTION 
The mechanisms underlying macrophage dysfunction in HIV/SIV infection are not well 
understood and are likely complex.  A popular hypothesis is that infection of macrophages 
contributes to defects in function.  Monocytes and macrophages are permissive to HIV in vitro 
and infected macrophages are readily found in tissues, including lymph nodes, brain, and vagina 
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[374-376].  In vitro macrophage exposure to viral proteins p24, Nef, and Tat are independently 
implicated in reducing phagocytic function, possibly by downmodulating FcγR-mediated 
signaling and/or mannose receptor expression [377-382].  Relative to CD4+ T cells, however, the 
proportion of SIV gag DNA+ macrophages across tissues is considerably minor [163].  Only in 
the absence of CD4+ T cells do macrophages emerge as the primary targets of viral infection, as 
established in separate macaque models involving experimental depletion of CD4+ T cells or use 
of a highly pathogenic SIV/HIV chimera [383, 384].  Interestingly, macrophage susceptibility to 
viral infection differs across tissues, with myeloid cells in spleen being highly susceptible and 
macrophages in the small intestine being almost entirely resistant due to TGF-β mediate 
downregulation of macrophage CCR5, CD4, and Nf-κB [163, 268, 385, 386]. 
Information concerning the effects of HIV/SIV infection on macrophages ability to 
secrete cytokines and the mechanisms underlying these responses are inconsistent.  Gene 
expression of LPS-related pattern recognition receptors TLR4 and CD14 are downregulated from 
unseparated PBMC after SIV infection, and alveolar macrophages isolated from HIV-infected 
lung have reduced responsiveness to TLR2/4 stimulation [203, 387].  Similarly, LPS-mediated 
activation and secretion of proinflammatory cytokines by monocyte-derived macrophages is 
inhibited by exposure to HIV Tat [201].  Instead, Tat and gp120 stimulation of monocyte-derived 
macrophages from healthy individuals is shown to induce anti-inflammatory IL-10 production 
[206, 207].  Interestingly, monocytes isolated from healthy donors and stimulated with LPS after 
in vitro infection with HIV, however, display heightened proinflammatory potential [201].  A 
separate study in untreated HIV infection showed that PBMCs from viremic patients have 
increased TLR6, 7, and 10 expression, and that individuals with advanced disease also 
upregulate TLR2, 3, and 4, which is reversed after viral suppression [388].  Moreover, 
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stimulation of monocytes from HIV-infected individuals through TLR2 results in increased 
TNF-α production [389]. 
In our study, macrophage function was assessed within the first 20 weeks of infection, a 
timepoint when tissue CD4+ T cell reservoirs are not as depleted as in AIDS.  Macrophages in 
gut mucosa, but not mesenteric lymph nodes, had impaired phagocytic activity that was 
associated with progressive SIV infection, despite both sites harboring detectable SIV gag RNA.  
Although macrophages are not permissive to HIV/SIV infection in small intestine, some 
evidence suggests newly recruited macrophages can be infected as monocytes prior to 
differentiation [182, 183].  CD16+ monocytes are more susceptible to infection than other 
monocyte subsets due to their expression of CCR5, and our data indirectly suggest that 
recruitment of this subset to gut mucosa is associated with phagocytic impairment [160, 184].  
Overall however monocytes represent an insignificant fraction of infected cells in blood 
compared to other susceptible cells in circulation, and therefore macrophage abnormalities as a 
result of direct monocyte infection are probably unlikely [385].  Furthermore, macrophages in 
both mesenteric lymph node and gut mucosa expressed little to no SIV p27 by flow cytometry in 
our study.  An alternative explanation could be that monocyte/macrophage engagement of viral 
proteins is negatively affecting their function by impacting the endocytic pathway and/or 
receptors that mediate phagocytosis.  Phagolysosomal fusion is significantly impaired after 
exposure of monocyte-derived macrophages taken from HIV-infected individuals to recombinant 
gp120 [390].  Indeed, there is a trend towards more intestinal cell-associated virus in progressors 
compared to controllers in our study and significantly more virus in plasma for gut-homing 
monocytes to encounter.  Furthermore, macrophage expression of mannose receptor, which 
facilitates non-opsonic binding and uptake of pathogen debris is reduced in HIV-infected lung 
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and correlated with an inability to phagocytose Pneumocystis carinii [391].  Observations of 
reduced complement-mediated phagocytic efficiency by monocyte-derived macrophages have 
also been reported in response to HIV infection [392].  It is possible newly differentiated 
macrophages might be abnormal even before accumulating in inflamed HIV/SIV-infected 
mucosa as a consequence of monocyte dysfunction.  Monocytes have reduced phagocytic 
function in the context of HIV infection, before or after TLR4 activation, compared to HIV-naive 
controls and the extent of monocyte impairment is accentuated in individuals with plasma viral 
loads >104 RNA copies/mL [393].  Interestingly, myeloid DCs and T cells have largely normal 
function in viremic nonpathogenic SIV models, indicating that environmental factors, such as 
differential levels of tissue inflammation, might play a more important role in influencing 
macrophage functionality than the presence of virus [20].   
Macrophages in lymph nodes from our study spontaneously produced TNF-α, IL-6, and 
IFN-α with infection, however comparatively, the levels of cytokines produced after ex vivo 
stimulation with viral agonists remained mostly unchanged.  Only with Env976-stimulated 
macrophages at week 20 did we see differences between controllers and progressors.  These data 
are mostly consistent with findings by others that lymph node macrophages are non-responsive 
or poorly responsive to TLR7/8 ligands after infection and that macrophages lose the ability to 
secrete IL-12 important for eliciting Th1 responses [100, 101].  The lack of information on 
lymph node macrophages, as compared to monocyte-derived or cell-line macrophages, makes it 
difficult to speculate on the molecular mechanisms underlying these data.  Interestingly, one 
study found that activation of monocyte-derived macrophages after in vitro HIV infection occurs 
through signaling pathways independent of TLRs, including calcium and MAPK, which can also 
induce Nf-κB expression [394].  It is possible that HIV evasion of TLR-signaling may 
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simultaneously involve suppressing TLR recognition, resulting in muted responses to external 
stimulation by TLR agonists seen by us in lymph nodes.  However, while we did not quantify 
macrophage infection in peripheral lymph nodes, macrophages in gut mucosal tissues were 
mostly devoid of virus.  Studies investigating TLR-expression and molecules that inhibit TLRs, 
such as IRAK-M, are urgently needed using sorted macrophages from tissues in the context of 
stable and progressive HIV/SIV infection to provide clarity on mechanisms underlying 
macrophage responses.   
6.7 ROLE OF GUT MACROPHAGE PHAGOCYTIC IMPAIRMENT IN 
PROGRESSIVE INFECTION 
Outside of the gut, reports of macrophage phagocytic defects are numerous in HIV/AIDS 
patients, depicting a potent inability to uptake and kill opportunistic pathogens such as 
Toxoplasma gondii, Staphylococcus aureus, Pneumocystis carinii, and Histoplasma capsulatum 
[197-199, 391, 395-397].  These data suggest that the high incidence of opportunistic infections 
in AIDS is in part a consequence of an inadequate host defense by macrophages.  Blood 
monocytes have also been reported impaired at various stages of HIV infection and thus 
implicated in inefficient pathogen control, although some groups report normal function [393, 
398, 399].  In our study, phagocytic impairment of macrophages in gut mucosa was evident at 
early chronic infection (week 20) in SIV progressors and was associated with intestinal 
macrophage burden, enterocyte loss, and plasma viral load.  A link between decreased 
macrophage phagocytic capacity, intestinal integrity, and microbial translocation was established 
in two recent studies using disparate animal models.  In the first study, the authors analyzed LPS-
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burden in SIVmac251-infected mucosal (colon, mesenteric lymph nodes) and peripheral (liver, 
axillary lymph nodes) tissues taken from rhesus macaques necropsied at early acute infection 
(<10 day post infection), late acute infection (14 to 28 days post infection), chronic infection 
without disease (168 to 396 days post infection), and AIDS [90].  They found that measures of 
E.coli were present in lamina propria of colon and in mesenteric lymph nodes by late acute 
infection but were not present in other tissues.  In animals with chronic infection and AIDS, 
however, E.coli products could be readily detected in mucosal and peripheral sites and 
corresponded with reduced in situ co-localization with HAM56+ macrophage in the gut.  In a 
separate study, the authors compared outcomes in HIV-infected humanized mice with mice 
treated with dextran sodium sulfate (DSS) to induce intestinal damage independent of infection 
[278].  Bacterial LPS levels were elevated in plasma from HIV-infected mice but only detected 
in DSS-treated mice after macrophages had been selectively depleted.  Ex vivo analysis of liver 
macrophage function from both groups revealed that impaired macrophage phagocytic function 
differentiated HIV-infected mice from DSS-treated mice.  Coupled with our findings of intact 
macrophage function in intestine from SIV controllers, these data collectively suggest a model in 
which a defective macrophage phagocytic response contributes to the diffusion and subsequent 
deposition of gut-associated microbes throughout the body in HIV/SIV infection.  
Pathogen-mediated inflammation is not likely to be the only consequence of impaired 
macrophage functionality.  Macrophage removal of apoptotic waste, a process known as 
efferocytosis, averts secondary necrosis caused by the release of noxious and immunogenic 
contents from within dead and dying host cells [112].  Defective clearance of host-derived 
apoptotic/necrotic debris by macrophages underlies the pathogenesis of neurological disorders, 
obesity, atherosclerosis, and inflammatory lung disease [400-403].  A study in mice found that a 
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deficit in macrophage ability to clear apoptotic cells at the site of diabetes wounds delays the 
wound healing process and prolongs inflammation [404].  In HIV-infected individuals, 
monocyte-derived macrophages have a decreased capacity to uptake apoptotic neutrophils, 
which studies in nonhuman primates demonstrate accumulate in blood from animals with 
pathogenic but not nonpathogenic SIV infection [405, 406].  Moreover, in vivo analysis of cell 
death by TUNEL staining in HIV-infected lymph nodes revealed TUNEL expression is strongly 
correlated with follicular hyperplasia and germinal center formation, and the authors posit that a 
build-up of apoptotic debris in lymph nodes could magnify immune activation through 
nonspecific stimulation of cells [407].  Consistent with this hypothesis, in our study, intestinal 
cell loss, a pathology driven by caspase-3 dependent apoptosis, was strongly correlated with gut 
macrophage abundance, suggesting macrophage recruitment to gut may be driven by increased 
enteropathy [328, 408].  It remains unclear whether increased cell death in HIV/SIV infection is 
a cause or consequence of chronic inflammation or reflects a positive feedback loop.  A recent 
study suggesting cell death contributes to the cycle of inflammation found that non-permissive 
quiescent CD4+ T cells, as opposed to activated CD4+ T cells, selectively undergo caspase-1 
dependent “pyroptotic” cell death in lymphoid tissue [409].  Caspase-1 activates the release of 
IL-1β and IL-18 from cells and initiates a highly inflammatory form of cell death intended to 
restrict bacterial growth but that can be detrimental if unregulated [282].  Although it would be 
difficult to quantify the relative burden of host cell waste as a source of inflammation and its 
relationship to macrophage function, it is clear that HIV/SIV infection induces widespread 
apoptosis of cells, and that macrophage ability to alleviate cellular debris through phagocytosis 
in animals progressing to disease, as demonstrated by us and others, is significantly 
compromised.     
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7.0  PUBLIC HEALTH SIGNIFICANCE 
Over 37 million people worldwide are currently infected with HIV, a virus that causes prolonged 
and irreversible damage to immune function and tissue health throughout the body [15, 410-
412].  Macrophages are effector cells of the innate immune system that participate in tissue 
maintenance and host defense by orchestrating inflammatory processes and ingesting cellular 
and foreign debris [114].  Alterations in macrophage biology are a hallmark of HIV/SIV 
infection, yet to date their heterogeneity across tissues has complicated interpretations of their 
role in disease control and progression [413].  This is a critical impediment that undermines our 
knowledge of HIV/AIDS pathogenesis and highlights the need for comprehensive, comparative, 
and systematic analysis of the macrophage response in different disease contexts across multiple 
tissues.  In this study, we found evidence that suggests the macrophage cytokine response 
contributes to the pathologic process of inflammation in lymph nodes in acute and early chronic 
SIV infection and in small intestine with AIDS, but likely does not significantly influence the 
course of disease.  Moreover, we found in SIV-infected small intestine, but not in mesenteric 
lymph nodes, that inadequate macrophage phagocytic function strongly correlated with a 
progressive SIV disease course and therefore could indirectly have proinflammatory 
consequences.  Collectively, these findings suggest that therapeutic strategies that preserve or 
regenerate macrophage phagocytic capacity may promote reduced pathology in tissues, including 
macrophage-derived inflammation in lymph nodes, and ultimately facilitate enterocyte renewal 
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and progress towards immune homeostasis.  One approach supported by proof of concept studies 
in rats proposes exploiting the specificity and function of receptor CD163 as a mechanism for 
drug entry into CD163+ macrophages [310]. 
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